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Abstract

A CONVERGENT APPROACH TO THE CONTINUOUS SYNTHESIS OF TELMISARTAN
VIA A SUZUKI REACTION BETWEEN TWO FUNCTIONALIZED BENZIMIDAZOLES

By Alex D. Martin. Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2015

Advisor: Dr. B. Frank Gupton, Professor of Chemistry, Professor and Chair of Chemical and
Life Science Engineering

A direct and highly efficient synthesis has been developed for telmisartan, the active
ingredient in the widely prescribed antihypertensive drug Micardis®. This approach brings
together two functionalized benzimidazoles using a high-yielding Suzuki reaction that can
be catalyzed by a homogeneous palladium source or palladium on a solid support.

xvii

The ability to perform the cross-coupling reaction was facilitated by the regiocontrolled preparation of a 2-bromo-1-methylbenzimidazole precursor. The method
developed is the first reported selective bromination at the 2-position of a benzimidazole
and produces the first major precursor in high yield (93%). The second precursor,
potassium

(4-methyl-2-propylbenzimidazol-6-yl)

trifluoroborate,

was

prepared

from

commercially available 4-bromo-2-methyl-6-nitroaniline. An optimized preparation is
described that provides a direct three-step process to prepare the benzimidazole and install
the borate; this synthetic sequence yields the second precursor with a 90% yield and no
isolated intermediates.
The two prepared precursors were combined with a third, commercially available
methyl-4’-(bromomethyl)-[1,1’-biphenyl]-2-carboxylate, utilizing a short sequence of high
yielding reactions to produce the telmisartan with an 83% yield from these advanced
intermediates. This new convergent approach provides the active drug ingredient with an
overall yield of 74% while circumventing many issues associated with the previously
reported processes. Additionally, a flow-based synthesis of telmisartan was achieved with
no intermediate purifications or solvent exchanges. The continuous process utilizes a
tubular reactor system coupled with a plug flow cartridge, ultimately delivering telmisartan in
an 86% isolated yield.

xviii

CHAPTER I
INTRODUCTION

1.1 Background and significance
In 2011, the World Health Organization reported that cardiovascular disease was the
leading cause of death in the world.1

Hypertension is a major risk factor for many

cardiovascular diseases (including strokes or aneurysms) and has been implicated in 16.5%
of all deaths.2 Hypertension or high blood pressure is classified when patient’s systolic and
diastolic blood pressures are above 140 torr and 90 torr, respectively. 3 Over 65 million
people in the United States alone are affected by hypertension.4
Telmisartan (1) is an antihypertensive drug currently marketed under the trade name
Micardis.5

This drug acts as an angiotensin receptor blocker (ARB).6 Pharmacological

agents targeting the renin-angiotensin system (RAS, Figure 1) have been explored since
the 1970s.7 The RAS begins with the cleavage of angiotensinogen by renin to form
angiotensin I. From there angiotensin-converting enzyme (ACE) converts the angiotensin I
into angiotensin II. Angiotensin II has a number of receptor subtypes, but the most important
is the type 1 receptor (AT1). When the AT1 receptor is stimulated the physiological response
includes increased vasoconstriction (by producing aldosterone), an increase in sodium and
water retention and the suppression of renin production. The two major groups of
compounds that have been used for the treatment of hypertension are ACE inhibitors and
ARBs. ARBs are the preferred clinical treatment, as ACE inhibitors have been found to

1

cleave other peptides besides the target (angiotensin I), which can lead to many sideeffects.

(image adapted from Burnier M, Brunner HR. Lancet. 2000, 355, 637-45)

Figure 1. Renin-angiotensin system

Telmisartan is the most efficacious member of the ARB drug class known as sartan
drugs which includes losartan (2), valsartan (3), candesartan (4) olmesartan (5) and more
(Figure 2).

Telmisartan has the longest half-life (24 h), a high protein binding affinity

(>99%) and a low daily dosage (40-80 mg).8 Additionally, it has been found to have
selective modulating activity of peroxisome proliferator-activated receptor gamma
(PPARG).9 This combined effect has been show to provide additional benefits against
vascular and renal damage caused by cardiovascular diseases,10 and it has been
suggested that it may also prevent cognitive decline in Alzheimer’s disease. 11 This high
value drug has recently lost patent protection (2014) in the United States, so the
development of a more efficient synthesis is timely and relevant endeavor.

2

Figure 2. Selected sartan drugs

1.2

Previously reported syntheses of telmisartan

1.2.1 Ries synthesis of telmisartan (1993)
The original telmisartan process was completed by Uwe Ries et al. in 1993 (Figure
3).12 This synthesis begins with the stepwise construction of the central benzimidazole ring
from 4-amino-3-methylbenzoic acid methyl ester (6). To produce methyl 4-methyl-2propylbenzimidazole-6-carboxylate (8), an amidation reaction with butyryl chloride is
performed, followed by a nitration reaction to install the nitro group ortho to the newly

3

formed amide. The nitro group is immediately reduced using palladium on carbon under an
atmosphere of hydrogen. An acid catalyzed cyclization forms the central benzimidazole
component (8).
With the first benzimidazole (8) formed, the route then proceeds to form the major
dibenzimidazole component. Saponification of the methyl ester of benzimidazole 8 is
followed by condensation with N-methyl-1,2-phenylenediamine (9) using polyphosphoric
acid (PPA) at elevated temperature (150-155 °C) to afford 1,7’-dimethyl-2’-propyl-2,5’dibenzimidazole (10). The elevated temperature and acidic conditions required during this
step adversely impact both product yield and purity – a major drawback of this original route
that has not been adequately resolved in subsequent process improvements. Alkylation with
4’-(bromomethyl)-2-biphenylcarboxylic acid tert-butyl ester (11) introduces the biphenyl
moiety to the 1-position of the central benzimidazole ring. Trifluoroacetic acid (TFA)
hydrolyzes the resulting ester to form the carboxylic acid, thus producing the final product,
telmisartan (1). This process produces the telmisartan in a 21% yield over 8 linear steps.

4

Figure 3. Ries synthesis of telmisartan

1.2.2 Reddy synthesis of telmisartan (2007)
In 2007, Reddy et al. published a process for telmisartan that utilizes the original
strategy but makes a number of improvements to increase purity and yield (Figure 4). 13
Starting

from

a

more

advanced

intermediate

(methyl

4-butyramido-3-methyl-5-

nitrobenzoate, 12) they produce the central benzimidazole by completing a palladium
catalyzed reduction of the nitro group to form the aniline which undergoes a basic catalyzed
cyclization in one-pot. The use of sodium hydroxide to cyclize the ring also hydrolyzes the
methyl ester producing 4-methyl-2-propyl-benzimidazole-6-carboxylic acid (13). The
carboxylic acid of benzimidazole 13 then undergoes a condensation reaction with N-methyl-

5

phenylene diamine (9), again at high temperatures in the presence of PPA, to produce the
dibenzimidazole (10). Methyl 4’-(bromomethyl)-(1,1’-biphenyl)-2-carboxylate (14) then
undergoes a nucleophilic substitution reaction to insert the biphenyl component. The
hydrochloride salt of the methyl ester of telmisartan (15) is isolated prior to the final
hydrolysis. Finally, to produce telmisartan potassium hydroxide is used to de-esterify the
methyl ester forming the carboxylic acid yielding telmisartan (1) with a 51% yield over 6
linear steps.
This process benefits from the availability of a more advanced starting material (12),
reducing the number of transformations by 2. The most notable improvement from this
reported method includes the use of a methyl ester (14) to replace the tert-butyl ester
located on the biphenyl moiety. This replacement provides a more atom economical
alternative that is also less expensive and easier to transform into the final carboxylic acid.
However, this process still does not address the use of PPA at the elevated temperatures.

6

Figure 4. Reddy synthesis of telmisartan

1.2.3 Goosen synthesis of telmisartan (2008)
The year after the Reddy paper was published Goosen and Knauben reported a new
process that involves a completely new approach to the assembly of the target molecule
(Figure 5).14 Beginning with an analogous starting material (3-methyl-4-nitrobenzoic acid,
16), this process starts in a very similar fashion to the previous two syntheses. Initially, the
nitro group of 16 is reduced using palladium on carbon and hydrogen. The resulting aniline
is then reacted with butyryl chloride to form the amide, followed by a nitration to insert a
nitro group ortho to the amide forming 4-butyramido-3-methyl-5-nitrobenzoic acid (17). In a
variation from the original strategy, the carboxylic acid 17 is then coupled with N-methyl
phenylene diamine (9) using 1,1’-carbonyldiimidazole (CDI), a peptide coupling reagent, to

7

form the outer benzimidazole ring though an in situ cyclization. The use of CDI forms the
bond that will eventually link the two benzimidazoles, while avoiding the problematic PPA
conditions. However, while the peptide coupling agents avoid the harsh conditions to form
the outer benzimidazole, the cost associated is much higher making them less practical for
commercial applications
Immediately following the cyclization a second palladium reduction yields N-(2amino-6-methyl-4-(1-methylbenzimidazol-2-yl)phenyl)butyramide (18). After the formation of
the outer benzimidazole, this process also introduces the biphenyl moiety in an alternative
way. First, isopropyl 4’-formyl-[1,1’-biphenyl]-2-carboxylate (22) is prepared utilizing a
decarboxylative cross-coupling reaction to couple 2-(4-chlorophenyl)-1,3-dioxolane (21) with
potassium 2-(isopropoxy-carbonyl) benzoate (20) formed in situ from phthalic anhydride
(19). With the central benzimidazole not yet formed, the biphenyl aldehyde 22 is used to
introduce the biphenyl moiety and a reductive amination reaction with the amine of
compound 18.
The reductive amination forms compound 23, with the outer benzimidazole formed
and the biphenyl moiety attached, leaving the penultimate acid catalyzed cyclization to form
the central benzimidazole. Finally, the saponification of the iso-propyl ester forms the final
carboxylic acid producing telmisartan (1). This route provides an overall yield of 43% over 9
steps.

8

Figure 5. Goosen synthesis of telmisartan

1.2.4 Kumar syntheses of telmisartan
In a span of two years, Kumar et al. published a number of publications on the
preparation of telmisartan (Figure 6). 15 The major difference introduced by this approach is
the use of a 4,4-dimethyloxazoline group, instead of an ester or a nitrile, as the precursor to
the final carboxylic acid.

9

Figure 6. Synthetic routes to prepare telmisartan reported by Kumar et al. (2009-2010)

10

In 2009, the first telmisartan synthesis to focus on the assembly of the biphenyl
moiety and the installation of the dibenzimidazole moiety was published. Starting from 2-(2bromophenyl)-4,4-dimethyl-2-oxazoline (25) and 4-hydroxymethylphenyl-boronic acid (26) a
Suzuki cross-coupling reaction was used to form the biphenyl species (28). The alcohol was
then converted to the chloride using thionyl chloride producing (4’-chloro-[1,1’-biphenyl]-2yl)-4,4,-dimethyl-2-oxazoline (29) which was reacted with dibenzimidazole 10 to produce the
oxazoline analogue of telmisartan 33. The 4,4’-dimethyl-2-oxazoline was converted to the
final product by refluxing in hydrochloric acid for 30 h to hydrolyze the oxazoline and form
the carboxylic acid. This process produces telmisartan with a 68% over 4 steps, but failed to
address the issues associated with the formation of the dibenzimidazole component of the
molecule.
Later in 2009, Kumar and coworkers published a similar synthesis using a new
coupling partner to form the biphenyl component. Starting with 4-formylphenyl boronic acid
(24) and the same aryl bromide 25, a Suzuki reaction was used to produce (4’-formyl-[1,1’biphenyl]-2-yl)-4,4-dimethyl-2-oxazoline (27). The aldehyde was reduced to form the alcohol
28, which is carried forward according to the previous synthesis producing telmisartan with
a 54% yield over 5 steps.
In 2010, Kumar published another process where they utilized the same chemistry
as above to produce the biphenyl aldehyde 27. However, instead of transforming the
aldehyde to the chloride and performing an alkylation, the aldehyde undergoes a reductive
amination with the intermediate 18, produced by the Goosen synthesis in 2008. After an
acid catalyzed cyclization to form the oxazoline analogue of telmisartan the oxazoline is
hydrolyzed according to the same hydrochloric acid reflux conditions they reported in 2009.
This process produces telmisartan with a 58% yield over 4 steps but varies very little from

11

the Goosen approach reported in 2008 utilizing an expensive peptide coupling reagent to
form the advanced intermediate 18.
The final paper published by Kumar and coworkers, again uses the dibenzimidazole
10 as a starting material. In this iteration they perform an alkylation reaction between 10 and
1-bromo-4-bromomethyl-benzene (30) to produce the dibenzimidazole with a bromophenyl
(31) instead of the biphenyl system. To form the biphenyl moiety, 4,4’-dimethyl-2-phenyloxazoline (32) is treated with n-butyl lithium and zinc chloride to form an organozinc
compound in situ that undergoes a Negishi coupling with the bromide of compound 31. This
reaction produces the oxazoline of telmisartan (33) with only a 55%, which is a major yield
hit that comes very late in the synthesis. Finally, compound 33 is carried forward to
telmisartan providing a poor overall yield of 37% over three steps.
Although Kumar reports a number of different approaches that utilize some unique
chemistry, they fail to address the major issues associated with preparation of telmisartan.
In three of the four cases they use the dibenzimidazole 10 as a preformed starting material.
In addition, much of the work completed was oriented towards the preparation of
appropriate analogues of the biphenyl oxazoline; however, the oxazoline is difficult to
hydrolyze requiring refluxing in hydrochloric acid for an extended period of time providing
little advantage to previously established strategies.

1.2.5 Wang synthesis of telmisartan (2012)
In 2012, Wang et al. published a new synthesis of telmisartan taking a unique
approach, to assemble the dibenzimidazole 10, by focusing on using less expensive
reagents and simple workups to provide a low cost production strategy (Figure 7). 16 Starting
with o-cresol (34), chloroform and sodium hydroxide are used to formylate para to the
hydroxyl group to produce 4-hydroxy-3-methylbenzaldehyde (35). Typically, formylation
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would occur ortho to the hydroxyl group; however, when the ortho position is occupied the
aldehyde is formed in the less active para position.

Utilizing a similar strategy to the

Goosen approach, Wang and coworkers elected to form the outer benzimidazole prior to
the formation of the central benzimidazole component. This is achieved by the nitration of
35 to produce 4-hydroxy-3-methyl-5-nitrobenzaldehyde (36), which is followed by a
methylation of the alcohol, providing 4-methoxy-3-methyl-5-nitrobenzaldehyde (37). To
reduce the cost associated with N-methyl phenylene diamine used in the previous
syntheses, a less expensive diamine is used, proceeding with phenylene diamine and
forming the benzimidazole under oxidative conditions using hydrogen peroxide. However,
the use of phenylene diamine requires methylation with dimethyl sulfate, after forming the
outside benzimidazole ring, producing 2-(4-methoxy-3-methyl-5-nitrophenyl)-1-methylbenzimidazole (39).
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Figure 7. Wang synthesis of telmisartan

With the outside benzimidazole in place, Wang and coworkers proceeded to make
the dibenzimidazole 10. To achieve the second cyclization the methoxy group, formed early
in the synthesis, is converted to an amine using ammonia to produce 2-methyl-4-(1-methylbenzimidazol-2-yl)-6-nitroaniline (40). The most elegant aspect of this synthesis is the use
of butyraldehyde (41) and sodium dithionite to form the central benzimidazole ring. This
reductive cyclization uses a less expensive reducing agent, replacing the palladium
catalyzed reductions used by others, to produce dibenzimidazole 10. The approach
shortens the process by eliminating the need for separate amidation, reduction and
cyclization reactions, forming the benzimidazole ring in one step. The process finishes the
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synthesis by then performing the alkylation using the bromide 14 and hydrolyzing the methyl
ester to produce telmisartan. They report a modest overall yield of 19% over 9 steps.

1.2.6 Wen patent process for telmisartan
In 2007, Wen et al. were issued a patent for the preparation of telmisartan (Figure
8).17 This approach starts with 4-amino-3-methylbenzoic acid methyl ester (6) and takes a
very similar approach to assembling the dibenzimidazole, but varies from the traditional
approach by performing simultaneous ring closures to form the dibenzimidazole. Wen and
coworkers reported transforming that original starting material (methyl 4-amino-3methylbnezoate, 6) to the carboxylic acid 17 in three steps. These three steps are almost
identical to the original process; however, each intermediate is isolated throughout the
cyclization process. The use of butyryl chloride (7) forms the amide (methyl 4-butyramido-3methylbenzoate, 42). Compound 42 is then nitrated ortho to the amide using nitric acid, to
produce compound 12, followed by the saponification of the methyl ester to produce 4butyramido-3-methyl-5-nitrobenzoic acid (17).
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Figure 8. Wen patent synthesis of telmisartan

This is where Wen deviates from the traditional approach. Instead of closing the
central benzimidazole, they use a peptide coupling reagent HBTU (N,N,N’,N’-tetramethyl-O(1H-benzotriazol-1-yl)uranium hexafluorophosphate) to couple the carboxylic acid of 17 with
N-methyl phenylene diamine (9). This produces a unique intermediate, N-(2-aminophenyl)4-butyramido-N,3-dimethyl-5-nitrobenzamide (43), which features two amides with neither
benzimidazole formed. The following transformation reduces the remaining nitro group to an
amine, which upon reflux in acetic acid leads to both benzimidazole rings forming
simultaneously to provide the dibenzimidazole 10 with a respectable yield of 78%. Following
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the concurrent ring formations the biphenyl moiety is introduces as the tert-butyl ester (11)
alkylating the 1-position of the central benzimidazole and is hydrolyzed using acetic acid to
produce the carboxylic acid telmisartan (1). This process provides the final product with a
32% yield over 8 steps. Although, the simultaneous ring closures provide a novel approach
to form the dibenzimidazole component (10) the process uses less than ideal methods to
prepare the required intermediate (43). The use of the expensive HBTU could and the need
to isolate every intermediate throughout the process can significantly increase the cost
associated with this preparation of telmisartan (1).

1.2.7 Commercial process for preparation of telmisartan
The current commercial process starts with the major dibenzimidazole component
(10) already formed and only includes the installation of the biphenyl moiety

and

subsequent formation of the carboxylic acid to produce telmisartan (1) (Figure 9).18 This
process uses 4’-(bromomethyl)-[1,1’-bihphenyl]-2-carbonitrile (45) as an alternative to the
more commonly used esters. The nitrile is produced in large volumes commercially and
provides a less expensive alternative while still providing a route to the carboxylic acid.
Dibenzimidazole 10 is alkylated by a base mediated substitution reaction to install the
biphenyl species producing the nitrile of telmisartan (46). The nitrile is hydrolyzed at high
temperatures (150-160 °C) in ethylene glycol and is then treated with concentrated
hydrochloric acid to produce telmisartan hydrochloride (47). After crystallization and a
charcoal treatment the pH is adjusted yielding telmisartan with an 80% yield over 4
transformations.
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Figure 9. Commercial patent synthesis of telmisartan

1.3

Project strategy

1.3.1 Retrosynthetic analysis of telmisartan
The previously reported syntheses of telmisartan, including the current commercial
process, rely on the formation of a functionalized dibenzimidazole via sequential cyclization
of appropriately substituted aniline precursors. The harsh conditions associated with this
very linear strategy result in significant byproduct formation resulting in lower yields. A more
convergent route that overcomes these issues by exploiting chemical reactions that are
both mild and selective can be envisioned. This novel synthetic strategy features breaking
telmisartan into three separate synthons (Figure 10). This proposed scheme takes a
completely new approach by coupling two dissimilar benzimidazole units to form the
dibenzimidazole using a Suzuki cross-coupling reaction, while introducing the biphenyl
moiety via a direct substitution reaction along with a functional group interconversion to
produce the desired carboxylic acid derivative.
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Figure 10. Retrosynthetic analysis of telmisartan

1.3.2 Recent advancements in chemical technologies
In the 20 years since the original telmisartan process, chemical technologies have
greatly improved providing more efficient and economical solutions to problems in synthetic
chemistry. Despite this, all of the previously reported syntheses of telmisartan still relied on
the sequential formation of each benzimidazole moiety through cyclization of appropriately
substituted aniline precursors. None of these routes represent a significant departure from
the original synthetic strategy nor have they addressed the major shortcomings associated
with the linear approach to the dibenzimidazole component of the molecule, namely the
significant byproduct formation and lower yields. This new approach to the total synthesis of
telmisartan is designed to improve efficiency and commercial viability while highlighting
three distinct advances in chemical synthesis: the Suzuki cross-coupling reaction, solid
supported catalysis, and continuous chemical processing.
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In 1979, Suzuki and Miyaura reported that aryl halides could react with
alkenylboranes with a palladium catalyst to form arylated E-alkenes.19 Since that time, the
Suzuki cross-coupling reaction has enjoyed broad application, ranging from the total
synthesis

of

complex

structures,

to

the

large-scale

commercial

production

of

pharmaceuticals.20 This Nobel Prize-winning chemistry uses mild reaction conditions that
are tolerated by a wide variety of functional groups, and the inorganic byproducts can be
removed easily.21 Telmisartan is an ideal candidate to attempt a Suzuki reaction, as it
features a carbon-carbon bond between two separate aryl rings.
Metal

catalyzed

cross-coupling

reactions

are

generally

completed

under

homogeneous conditions, using catalysts that are soluble in the reaction mixture. These
types of reactions are great tools for creating carbon-carbon bonds and are used widely
throughout the pharmaceutical industry. While homogeneous catalysis use is common,
challenges still remain. The most notable disadvantages include the lack of recyclability, the
need for ligands to stabilize the catalyst and the potential for contamination of the final
product with toxic metals. Solid supported catalyst systems, in which the catalytic metal is
deposited onto a solid support, provides a heterogeneous alternative to the use of soluble
catalysts. Solid supported catalyst systems have typically shown decreased activity. Recent
developments have produced new catalysts that can combine high activity and high stability
while providing a recyclable catalyst that is easily separated from the product.22 Specifically,
palladium deposited on graphene sheets has been the subject of a number of recent
studies.23 The unique structure and electronic properties of graphene provide access to a
solid support that is stable, active, ligand free and recyclable. 24
Finally, we hope to use the total synthesis of telmisartan to showcase the benefits of
continuous process chemistry, or flow chemistry. Flow reactors have been developed that
can provide safer and more efficient chemical transformations. Small channels or tubing
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provide a large surface to volume ratio25, allowing improved heat transfer and component
mixing throughout the reaction mixture.26 This technology also provides a much easier
progression for scale-up. To increase production, a single reactor could be run for a longer
time or more reactors could be added in parallel.
In principle, these advances in chemical technology encourage the consideration of
a convergent assembly of telmisartan as opposed to the linear approach of previous
syntheses. The methodology described herein will provide a more efficient assembly of the
target molecule, while avoiding the problematic reaction conditions associated with the
existing synthetic methods and ultimately provide a continuous chemical process to prepare
telmisartan.
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CHAPTER II
PREPARATION OF 2-BROMO-1-METHYLBENZIMIDAZOLE

2.1

Background
Benzimidazoles represent a promising group of potential pharmacophores.27

Benzimidazole containing compounds have been reported to show a wide range of
biological activities including: antimicrobial28, anticancer29, antiviral30, anti-inflammatory31,
antidiabetic32, anticonvulsant33, and antihypertensive34 (Figure 11). Most of these
compounds have some functionalization at the 2-position. Therefore, finding new ways to
introduce selective functionalization at the 2-position could prove to be extremely useful in
further drug discovery as well as in the streamlining of current synthetic routes. With
regards to telmisartan, based on the retrosynthetic analysis previously discussed, 2-bromo1-methylbenzimidazole (54) was identified as a potential candidate to be used in the
introduction of the outer benzimidazole component of the molecule.
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(structures from Shah K et al. Med Chem Res. 2013. 22, 5077-104.)

Figure 11. Pharmacologically active compounds that contain the benzimidazole moiety

There have been a number of previously reported methods for the preparation of 2bromo-1-methylbenzimidazole (54). There are a significant number of drawbacks as these
approaches are typically lengthy and low yielding processes. The goal of this project was to
develop a selective one-step preparation of compound 54 from commercially available 1methylbenzimidazole (55) (Figure 12). Inability to access this compound may provide
insights into why this approach has not been previously considered.

Figure 12. Retrosynthetic analysis of 2-bromo-1-methylbenzimidazole
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2.2

Previously reported syntheses of 2-bromo-1-methylbenzimidazole

2.2.1 Ellingboe synthesis of 2-bromo-1-methylbenzimidazole (1992)
The first synthesis was reported in 1992 by Ellingboe et al (Figure 13).35 They found
that

4-[(methylsulfonyl)amino]benzamides

and

sulfonamides

containing

a

2-

aminobenzimidazole group were the most potent as a Class III antiarrhythmic. The bromo
group in the 2-position was used to substitute the 1-methylbenzimidazole onto a secondary
amine attached to the benzamide/sulfonamide.

Starting from 2-mercaptobenzimidazole

(56) the thiol group is transformed to the bromide using molecular bromine and
concentrated hydrobromic acid to form 2-bromobenzimidazole (57). Finally, to produce 2bromo-1-methylbenzimidazole (54), the 1-position of benzimidazole 57 is methylated using
dimethyl sulfate under basic conditions. This approach produced 54 in a 51% yield over two
steps.

Figure 13. Ellingboe preparation of 2-bromo-1-methylbenzimidazole

2.2.2

Boga synthesis of 2-bromo-1-methylbenzimidazole (2000)
In 2000, Boga and coworkers reported a method using tetrahalogenmethanes as

reagents to halogenate heterocycles using a lithium-halogen exchange (Figure 14).36
Starting with 1-methylbenzimidazole (55), butyl lithium is used to selectively lithiate at the 2position producing 2-lithio-1-methylbenzimidazole (58). Immediately following the lithiation
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carbon tetrabromide is used to introduce a bromide into the 2-position using a metalhalogen exchange, producing 2-bromo-1-methylbenzimidazole (54) in a 65% yield.
However, in addition to the modest yield associated with this method there is a small
amount of 2-(dibromomethyl)-1-methylbenzimidazole (59) from the side reaction of the
lithium intermediate reacting with the dibromocarbene, a byproduct from the initial metalhalogen exchange.

Figure 14. Boga preparation of 2-bromo-1-methylbenzimidazole

2.2.3 Costanzo synthesis of 2-bromo-1-methylbenzimidazole (2005)
More recently, Costanzo (2005)37 reported a one-step preparation of 2-bromo-1methylbenzimidazole (54) from now commercially available 2-bromobenzimidazole (57)
(Figure 15). This method uses dimethyl sulfate to methylate the 1-position, similar to the
method reported by Ellingboe. However, this process provides a more optimized conversion
and increases the production of compound 54 with a moderate yield of 79%.

Figure 15. Costanzo preparation of 2-bromo-1-methylbenzimidazole
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2.2.4 Zornik synthesis of 2-bromo-1-methylbenzimidazole (2011)
Six years later, Zornik (2011)38 reports a high yielding process using methyl iodide
and sodium hydride to perform the same methylation (Figure 16). By performing the
methylation this way the yield was increased to 98% and provided an easier purification
method. Although, this reaction proceeds in very high yields, methyl iodide is significantly
more costly when compared to the dimethyl sulfate methods.

Figure 16. Zornik preparation of 2-bromo-1-methylbenzimidazole

2.2.5 Verna synthesis of 2-bromo-1-methylbenzimidazole (2013)
In 2013, Verna et al. reported a preparation of 2-bromo-1-methylbenzimidazole (54)
from o-phenylene diamine (38) (Figure 17). To start the diamine 38 is reacted with carbon
disulfide and acetic acid to form 2-mercaptobenzimidazole (56). The thiol is transformed to
the bromide using the method reported by Ellingboe producing compound 57, which is then
methylated using dimethyl sulfate to produce compound 54. This three step process
produces 2-bromo-1-methylbenzimidazole (48) in 45% overall yield.
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Figure 17. Verna preparation of 2-bromo-1-methylbenzimidazole.

2.3 Development

of

a

selective

bromination

of

1-methylbenzimidazole

at the 2-position
Recently, 2-bromo-1-methylbenzimidazole (54) has become commercially available,
but currently the cost is prohibitive towards scalable usage. The previously reported
processes provide a wide variety of options to produce the desired compound, but leave
room for significant improvement. The goal moving forward is to delineate reaction
conditions that allow for the selective bromination of 1-methylbenzimidazole at the 2position without the use of prefunctionalized starting materials.

2.3.1 Background on bromination of benzimidazoles
In 1996, Kawasaki briefly mentions the use of N-bromosuccinimide (NBS) to form
the bromide at the 2-position of a benzimidazole.39 This method provided a yield of 74%;
however, specific conditions were not identified. Previously, Mistry reported a process for
non-selective bromination of benzimidazole (60) using NBS producing 57 with a 67% yield
over 1 step (Figure 18).40 From this report it is evident that benzimidazoles are susceptible
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to bromination at multiple sites. In some cases, especially in the presence of excess NBS,
multiple sites can be brominated on the same molecule producing dibrominated or
tribrominated species.

Figure 18. Mistry bromination of benzimidazole

Based

on

the

above

references,

brominating

commercially

available

1-

methylbenzimidazole (55) using NBS was chosen as the most promising method moving
forward. The goal was to achieve a commercially viable method for the selective
bromination at the 2-position of 1-methylbenzimidazole in high yield.

2.3.2 Room temperature bromination studies of 1-methylbenzimidazole
A variety of commonly used solvents were selected for room temperature
experiments to define selective bromination conditions. It was apparent from this initial
work, that the 1-methylbenzimidazole (55) was susceptible to bromination at multiple sites.
Depending on the solvent, the benzimidazole could be brominated at the 2, 5, 6 or any
combination of positions. At room temperature a number of solvents provided the desired
product (2-bromo-1-methylbenzimidazole, 54), although the yields are very low (Table 1).
Dichloromethane (DCM) and carbon tetrachloride (CCl4) both show 37% conversion to
compound 54, but both also show a significant amount of other products (entries 1 and 4).
The more polar solvents dimethyl formamide (DMF) and methanol (MeOH) showed a
preference for the other brominated products with only 7% of compound 54 in DMF (entry 2)
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and no desired product formed in MeOH (entry 3). Finally, tetrahydrofuran (THF) was found
to produce only 11% of 2-bromo-1-methylbenzimidazole (54); however, despite the low
conversion to desired product, no other products were seen (entry 5). This was a promising
discovery and led to further exploration into improving the yield while maintain this
selectivity.

Table 1. Bromination of 1-methylbenzimidazole at
room temperature with 1 equivalent of NBS

a

entrya

solvent

NBS (equiv.)

54b

other productsc

1

DCM

1

37

11

2

DMF

1

7

21

3

MeOH

1

0

69

4

CCl4

1

37

12

5

THF

1

11

0

b

c

55 (0.76 mmol), NBS (0.80 mmol), 4 mL solvent. % Conversions determined by GC-MS. Mixture of di-,
and tribrominated byproducts.

In an attempt to increase the amount of desired product, the amount of NBS was
increased from 1 to 3 molar equivalents (Table 2). In all cases the consumption of the
starting material increased. Both DCM and MeOH were found to show 100% of the
benzimidazole reacted; however, no desired product was produced (entries 1 and 3).
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In the case of DCM, despite the appearance of the desired product with only 1
equivalent of NBS, none was found when excess brominating agent was used. It is likely
that over bromination occurred and a mixture dibromo species included bromides at the 2position. DMF shows an increase in desired product (18% up from 7% at 1 equiv.), but a
similar increase to 44% was observed in other products (entry 2). In the case of THF, a low
conversion of 32% was found (entry 4). However, the increase of NBS did not lead to any
over-bromination as observed with the other solvents tested. This observation was a
promising development while trying to provide selective bromination at the 2-position.

Table 2. Bromination of 1-methylbenzimidazole at
room temperature with excess NBS

a

entrya

solvent

NBS (equiv.)

54b

other productsc

1

DCM

3

0

100

2

DMF

3

18

44

3

MeOH

3

0

100

4

THF

3

32

0

b

c

55 (0.76 mmol), NBS (2.3 mmol), 4 mL solvent. % Conversions determined by GC-MS. Mixture of diand tribrominated byproducts.
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2.3.3 Microwave assisted bromination of 1-methylbenzimidazole
With the goal of increasing the conversion to optimum levels and maintaining the
selectivity trend seen with THF a microwave-assisted solvent screen was performed and
provided additional insight (Table 3). Using the higher amount of NBS, every solvent tested
showed complete consumption of the starting material. This solvent screen revealed that
almost every solvent tested yielded undesired mixtures of byproducts. Similar to the room
temperature studies, it was found that THF provided selectivity to the 2-position and affords
essentially complete conversion to the desired product (entry 8).

Table 3. Microwave assisted bromination of 1-methylbenzimidazole

a

entrya

solvent

NBS (equiv.)

54b

other productsc

1

Toluene

3

0

100

2

DMF

3

0

100

3

ACN

3

0

100

4

Diglyme

3

0

100

5

EtOAc

3

0

100

6

Et2O

3

0

100

7

ClBn

3

0

100

8

THF

3

100

0

b

c

55 (0.76 mmol), NBS (2.3 mmol), 4 mL solvent. % Conversions determined by GC-MS. Mixture of diand tribrominated byproducts.
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2.3.4 Bromination

of

1-methylbenzimidazole

using

conventional

heating conditions
With the information from the microwave-assisted solvent screen, conventional
heating conditions were explored to provide a more easily scalable process for the
preparation of 2-bromo-1-methylbenzimidazole (54). By refluxing the reaction for 1 hour in
THF with 3 equivalents of NBS, an isolated yield of 93% was achieved (Figure 19).

Figure 19. Selective bromination of 1-methylbenzimidazole

This is the first reported example of a selective and scalable bromination of 1methylbenzimidazole (51) at the 2-position and is an essential element of the convergent
strategy described earlier41. This selective method could find utility in the preparation of
other benzimidazole adducts in the future and possibly be applied to other similar
heterocycles as well.

2.3.5 Proposed mechanism for bromination of 1-methylbenzimidazole
It is unclear what provides the selectivity for the 2-position, with no over bromination.
Solvents with similar polarities as THF, such as ethyl acetate (EtOAc) and chlorobenzene
(ClBn), did not show the same selectivity. Similarly, other ethers tested, ethyl ether (Et2O)
and bis(2-methoxyethyl) ether (also known as diglyme), did not afford the desired product. It
is possible that solvent cage effects play a role, due to the radical based mechanism for the
reaction (Figure 20). The nitrogen bromide bond is cleaved (initiated by heat) producing a
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free radical bromine. The bromine abstracts a hydrogen from the 2-position of the
benzimidazole 51, producing hydrobromic acid and the benzimidazole radical 58. The
hydrobromic acid then reacts with a second NBS molecule to produce molecular bromine
and succinimide (57). The molecular bromine then reacts with the benzimidazole radical
producing the desired 2-bromo-1-methylbenzimidazole (48) and regenerating a bromine
radical to further propagate until the reaction is completed.

Figure 20. Proposed mechanism for bromination of 1-methylbenzimidazole using NBS

It is not known what provides this excellent selectivity; however it is hypothesized
that certain physical properties of THF account for the observed reaction. NBS can act as
an electrophilic bromine source in addition to the radical mechanism described earlier. It is
thought that the use of NBS in other solvents can react via a different mechanism entirely or
in addition to the radical mechanism. In this case, peroxides present in low levels in the THF
itself can act as a radical initiator. Additional stabilization of the bromine radical can be
attributed to solvent cage effects. The geometry and polarity of the five-member ring could
theoretically match the imidazole portion of the benzimidazole leading to directing affects to
the 2-position by physically replacing a THF molecule in the solvent cage.
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CHAPTER III
PREPARATION OF POTASSIUM (4-METHYL-2-PROPYLBENZIMIDAZOL-6-YL) TRIFLUOROBORATE

3.1

Background
With the first precursor (2-bromo-1-methylbenzimidazole, 54) in hand, the candidate

for the second precursor was identified as potassium (4-methyl-2-propylbenzimidazol-6-yl)
trifluoroborate (65).

4-bromo-2-methyl-6-nitroaniline (66) was chosen as the starting

material, as it is commercially available and has the functionalization in place that can allow
for a direct route to compound 65 (Figure 21). In order to prepare the benzimidazole 65
from the bromo-nitroaniline 66, two major transformations were identified. The first step is
the formation of the benzimidazole utilizing the ortho nitro and amino groups. Additionally,
the bromo substituent provides an easy path for the installation of the required boron
species, needed for the proposed Suzuki cross-coupling reaction.

Figure 21. Retrosynthetic analysis of potassium (4-methyl-2-propylbenzimidazol-6-yl)
trifluoroborate

34

3.2

Synthetic strategies for the preparation of functionalized benzimidazoles
As previously mentioned, benzimidazole structures have shown a wide-range of

biological activity. A considerable amount of work has been completed, developing many
different ways to synthesize derivatized benzimidazoles. This work has span over a
hundred years. These routes provide several options leading to a variety of functionalized
benzimidazole compounds.

3.2.1 Formation of benzimidazoles from arylene diamine and carbonyl
The most commonly reported route to benzimidazole core structures involves a
condensation reaction between an arylene diamine and one of any number of carbonyl
equivalents (Figure 22). This route starts with an o-phenylene diamine (67) which can react
with carboxylic acids or their derivatives, such as acid chlorides, esters or anhydrides.42
Once the condensation is completed the intermediate o-aminophenyl amide (68) is formed
and can undergo an acid catalyzed cyclodehydration reaction producing the desired
functionalized benzimidazole (69). The use of acid chlorides is much more prevalent, when
compared to the other options, due to higher reactivity. The other options sometimes
require harsh reaction conditions and typically limit the scope to a small set of tolerable
functional groups.

Figure 22. Preparation of benzimidazoles from arylene diamine and carbonyl
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3.2.2 Formation of benzimidazoles from arylene diamine and nitriles, amides, or imidates
Arylene diamines have been found to also react with nitriles 43, amides44 and even
imidates45 (Figure 23). These compounds, in the presence of hydrochloric acid (HCl),
undergo a Pinner reaction to form o-aminophenyl amidines (70).

Due to the acidic

conditions, the amidine is then subsequently cyclized in situ releasing ammonia. This
cyclization produces the functionalized benzimidazole (69). This strategy provides an
alternative route to the more commonly used carbonyl derivatives described above.

Figure 23. Preparation of benzimidazoles from arylene diamine and nitriles/amides/imidates

3.2.3 Formation of benzimidazoles from bromoanilines and amides
Much more recently, similar to the example above, o-bromoanilines (71) have been
used to form analogous amidine structures (Figure 24). The amine group of the aniline (71)
reacts with primary or secondary amides to produce an intermediate o-bromophenyl
amidine species (72) via a phosphoryl chloride facilitated condensation.

The final

benzimidazole (73) is formed by a palladium catalyzed N-arylation providing a
benzimidazole with the potential for introducing functionalization at the 1-position as well.46
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Figure 24. Preparation of benzimidazoles from bromoanilines and amides

3.2.4 Formation of benzimidazoles from aryldiamines and aldehydes
Aldehydes

also

have

been

used

to

produce

benzimidazoles

from

o-

phenylenediamines (Figure 25). When an aldehyde undergoes condensation with the
diamine (67)47 the benzimidazoline intermediate (74) is produced. This intermediate can
than proceed through an oxidation and subsequent elimination to produce the
benzimidazole 69.48 This route utilizes mild reaction conditions, such as oxone at room
temperature; however, the oxidation may occur spontaneously via a disproportionation
reaction

leading

to

side

products.

Additionally,

cases

forming

nonsymmetrical

benzimidazoles may lead to a mixture of products. Ketones have also been reported to
undergo a similar reaction,49 but due to the need for the elimination of an alkyl group to form
the final benzimidazole, this process can lead to a mixture of products when the ketone
possesses dissimilar alkyl groups. This limits the feasibility of the use of ketones for many
target molecules.

Figure 25. Preparation of benzimidazoles from arylene diamines and aldehydes
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3.2.5 Formation of benzimidazoles from nitroanilines and aldehydes
The most recent approach that has been reported uses aldehydes and onitroanilines to form the benzimidazole through a benzylidene (68) intermediate (Figure 26).
This approach completes transformation in one-step by forming the benzylidene in situ
followed by the intramolecular reductive cyclization to form the benzimidazole 61. This
reaction has been completed using a wide range of reducing agents 50 and provides a direct
one-step path from nitroaniline to the desired benzimidazole.

Figure 26. Preparation of benzimidazoles from arylene diamines and aldehydes

3.3 First generation process to prepare trifluoroborate (65) via three-step cyclization
In order to expedite preliminary experiments for the key Suzuki reaction, a
straightforward and accessible route to the second precursor (potassium (4-methyl-2propyl-benzimidazol-6-yl) trifluoroborate, 65) was conceived. This route was chosen with a
goal of feasibility, rather than elegance, to provide the proposed Suzuki partner rapidly. A
more efficient second generation approach to this synthon was developed in parallel with
the exploratory studies for the Suzuki cross-coupling reaction, with the goal of optimizing
this route towards a more streamlined process.

3.3.1 Amidation of 4-bromo-2-methyl-6-nitroaniline
Initially, the cyclization was attempted first utilizing a route similar to the chemistry
originally laid out by Ries and coworkers. It was proposed that the starting material (4-
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bromo-2-methyl-6-nitroaniline, 66) would undergo amidation, followed by a palladium
catalyzed reduction of the nitro group and then finally cyclized to the benzimidazole under
acidic conditions.
The amidation of nitroaniline 66 was completed using butyryl chloride (7) as the
acylating reagent (Figure 27). By heating a mixture of the two compounds in ClBn for 2
hours at 100°C a good conversion was found by HPLC. In addition to the desired product
77, a small amount of byproduct was also observed resulting from double amidation. In the
presence of excess butyryl chloride the proton on the newly formed amide can be replaced
by an additional amidation reaction. Conditions were found to maximize the production of 77
while limiting the amount of over amidation, providing the desired amide with an isolated
yield of 82%.

Figure 27. Amidation of 4-bromo-2-methyl-6-nitroaniline

3.3.2 Dehalogenation during palladium catalyzed hydrogenation
After the amide 77 was formed the next step was a palladium catalyzed
hydrogenation reaction, intended to reduce the nitro group to facilitate cyclodehydration to
the benzimidazole. The isolated N-(4-bromo-2-methyl-6-nitrophenyl)-butyramide (77) was
reduced using palladium on carbon in the presence of hydrogen. However, no desired
product was observed. Instead of an o-aminophenyl amide species (78) an unexpected
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benzimidazole was formed (Figure 28). In this case, palladium

catalyzed the

dehalogenation of the 77.51 In addition to reduction of the starting material, the
dehalogenation event generated hydrobromic acid which then catalyzed the cyclization of
the reduced intermediate 79 to form 4-methyl-2-propylbenzimidazole (80).

Figure 28. Dehalogenation of halide during Pd hydrogenation.

3.3.3 Palladium catalyzed installation of boronate with pinacol diboron
In order to preclude the problematic dehalogenation of compound 77, efforts were
redirected towards the installation of the boron species prior to reduction of the nitro group.
Bis (pinacolato) diboron (81, B2pin2) was initially chosen as the boronating reagent due to its
prevalent use throughout literature52 and its compatibility with downstream steps. To
complete this transformation a palladium catalyst was used to replace the halogen with a
boron species via a similar mechanism to the Suzuki reaction. 53 However, the boronation
with compound 77, it was unsuccessful in producing the desired compound 82. It was found
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that the base required for the activation of the boronate installation leads to the cleavage of
the amide bond (Figure 29).

Figure 29. Unsuccessful installation of pinacol boron to amide 77

In 2008, Velaparthi reported conditions to install the pinacol ester to 4-bromo-2methyl-6-nitroaniline (66) using the diboron reagent in the presence of a palladium
catalyst.54 These conditions have the potential to be extremely effective, but also proved to
be susceptible to alternative reaction pathways, as a major byproduct was observed during
our preliminary experiments.
This byproduct was identified as the bianiline species (84) and it initially appeared to
be the product of homocoupling between two molecules of the starting material (66).
However, a more in-depth study of the reaction revealed a different mechanism for
formation of the bianiline byproduct 84 (Figure 30). HPLC monitoring of the reaction mixture
over time revealed formation of the desired boronic acid pinacol ester product (83) at early
time-points. Under certain reaction conditions, both the product (83) and the bianiline (76)
species were observed. As the reaction proceeded the decrease in the observed quantity
of boronic ester (83) could be correlated to an increase in the bianiline byproduct (84).
These observations led to the conclusion that the bianiline is most likely not the artifact of a
direct homocoupling between two molecules of the starting bromoaniline (66). Rather, the
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unwanted byproduct is likely caused by a Suzuki reaction between the desired product (83)
and an unreacted bromoaniline (66), catalyzed by the palladium catalyst required for the
installation of the pinacol boron ester.

Figure 30. Proposed route to bianiline byproduct 84.

3.3.4 Optimization studies for installation of pinacol boron to nitroaniline 66
In an attempt to find conditions to minimize the amount of bianiline byproduct (84)
being formed a set of reactions were screened in order to gain a better understanding of
how specific process parameters contribute to byproduct formation (Table 4). The three
factors studied were catalyst loading, equivalents of diboron reagent and reaction
concentration. The reaction of 4-bromo-2-methyl-6-nitroaniline (66) and pinacol diboron (81)
was

run

in

the

presence

of

only

2

mol%

of

the

catalyst,

[1,1’-

bis(diphenylphosphino)ferrocene] dichloropalladium (PdCl2dppf) and only a slight excess of
diboron.
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These conditions resulted in low conversion to the desired product (24%, entry 1)
and produced a similar amount of byproduct (25%) while the remaining starting material
remained unreacted. An increase in catalyst loading (entry 2), led to complete consumption
of the starting material and increased the yield of 83 up to 63%, but also increased the
amount of bianiline 84 to 37%. Alternatively, by increasing the amount of diboron to 5
equivalents (entry 6) a significant improvement was noticed. The large excess of the
boronating reagent produced a much higher conversion of 74% with only 8% of the bianiline
byproduct (84) formed.
Finally, optimal conditions were found by running the reaction in a more
concentrated solution (entries 8 and 9). Using the higher amounts of the palladium catalyst
and the pinacol diboron reagent, the higher reaction concentration led to complete
conversion to the desired (4-amino-3-methyl-5-nitrophenyl) pinacol boron (83) with no
byproduct observed.
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Table 4. Effects of process parameters on boronation of
4-bromo-2-methyl-6-nitroaniline

a

entrya

B2pin2 (equiv.)

DMSO (mL)

Pd (mol%)

83b

84b

1

1.05

4

2

24

25

2

1.05

4

10

63

37

3

1.05

1

2

74

26

4

1.05

1

10

81

19

5

2.5

2

5

93

7

6

5

4

2

74

8

7

5

4

10

95

5

8

5

1

2

97

3

9

5

1

10

100

0

b

77 (0.43 mmol), KOAc (1.3 mmol), under nitrogen at 100°C for 5 h. Conversions determined by HPLC

Although this first screen provided reaction conditions that avoided byproduct
formation, the high cost of both the palladium catalyst and the pinacol diboron reagent
resulted in concerns about the cost impact of this reaction. With the intermediate reaction
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conditions (Table 4, entry 5), which lowers catalyst, diboron, and reaction concentration
each by half, a reasonable conversion of 93% could be achieved. With that in mind a
secondary screen was aimed at optimizing conversion while taking into account the cost
associated with the components (Table 5). It was found that the reactions with highest
concentration provided excellent conversion with minimal by product. Reactions with only 2
equivalents of B2pin2, ranging from 2 mol% catalyst up to 10 mol%, all showed conversions
above 90%.

Table 5. Effects of catalyst loading on boronation of 4-bromo-2-methyl-6-nitroaniline.

a

entry

B2pin2 (equiv.)

DMSO (mL)

Pd (mol%)

83

84

1c

2

1

2

96

4

2

2

1

5

97

3

3

2

1

10

98

2

b

77 (0.43 mmol), KOAc (1.3 mmol), under nitrogen at 100°C for 5 h. Conversions determined by HPLC

The reaction of 4-bromo-2-methyl-5-nitroaniline (66) and pinacol diboron (81, 2
equiv.) in the presence of PdCl2dppf (5 mol%) led to the formation of the desired (4-amino3-methyl-5-nitrophenyl) boronic acid pinacol ester (83) with an isolated yield of 95% (Figure
31).
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Figure 31. Pinacol boron installation to form 83.

3.3.5 Formation of benzimidazole via three-step cyclization
With the installation of the boron complete, nitroaniline 83 was successfully
converted to the benzimidazole without concern for cleavage at the 6-position. This overall
transformation was carried out through a series of non-isolated intermediates (Figure 32),
constituting a slight modification to the original process developed by Ries. 12 Starting with
(4-amino-3-methyl-5-nitrophenyl) boron acid pinacol ester (83) a slight excess of butyryl
chloride (7) is added. When heated in chlorobenzene the reaction forms the corresponding
amide (85). After a solvent exchange to methanol, palladium on activated carbon is
introduced to solution and then the reaction is stirred under an atmosphere of hydrogen.
This leads to the catalytic hydrogenation of the nitro group to produce the o-aminophenyl
amide (86). Then after refluxing in acetic acid to facilitate the cyclodehydration, 4-methyl-2propylbenzimidazol-6-yl boronic acid pinacol ester (87) is isolated with a 63% yield over the
three steps. It was observed that some cyclization can occur without the AcOH reflux step.
It is likely due to the HCl formed during the amidation step. However, the AcOH is required
to achieve a higher yield, assisted by the elevated temperature.
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Figure 32. Three-step cyclization to form benzimidazole 87.

3.3.6 Formation of potassium trifluoroborate salt 65
With the benzimidazole formed and a boron species installed one final
transformation is needed to convert synthetic intermediate 87 into a trifluoroborate salt, the
desired synthon for the proposed convergent approach to telmisartan. Trifluoroborates have
been shown to have a wide range of benefits over more traditional boronic acid
derivatives.55 For example trifluoroborates are typically easy to purify out of solution. Most
trifluoroborates have very limited solubility in aqueous systems and most organic solvents,
and can therefore often be precipitated out of the reaction mixture. They are also highly
stable compounds being able to tolerate the presence of air and water while being stored.
Finally, and most importantly, trifluoroborates have been found to be more reactive towards
Suzuki cross-coupling reactions as compared to other boron species. This is likely due to
the fact that trifluoroborates already have a quaternary boron, which is activated to undergo
the transmetallation step in the catalytic cycle of the Suzuki reaction.
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To form a trifluoroborate from a pinacol ester, potassium bifluoride (KHF2) is used,
and it tends to react quickly and give very high yields.56 In this case, the pinacol ester of
benzimidazole 87 was found to show complete conversion to the trifluoroborate 65. As
aqueous KHF2 is added to the benzimidazole 87 in a THF solution the reaction would
proceed in an unusual THF/water biphasic system. After stirring at room temperature the
product is easily purified by removing the THF and filtering the precipitate that is formed.
In order to maximize the amount of product being formed and streamline the
process, formation of the desired trifluoroborate salt (65) was telescoped with the previous
synthetic sequence. When all five steps, starting from the nitroaniline (66) ,are completed
without any isolation, the final Suzuki partner (65) can be produced and easily isolated in
pure

form.

This

method

provides

potassium

(4-methyl-2-propylbenzimidazol-6-yl)

trifluoroborate in five steps with an isolated yield of 60% (Figure 33).

Figure 33. Five-step formation of trifluoroborate 65 nitroaniline 66

3.3.7 Formation of potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate
An alternative approach was also explored and experiments were performed
converting the pinacol boron of the nitroaniline 83 to the trifluoroborate (88) (Figure 34).
This transition occurred with good conversion producing the desired potassium (4-amino-3methyl-5-nitrophenyl) trifluoroborate (88) with a 93% isolated yield. However, attempts to
carry the nitroaniline 88 forward to the benzimidazole proved to be unsuccessful. The
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significant solubility issues proved problematic and in some cases it appeared the boroncarbon bond was cleaved during cyclization attempts.

Figure 34. Formation of potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate

3.4 Second generation process to prepare trifluoroborate (65)
via reductive cyclization
Although the first generation route to the trifluoroborate salt 65 offers a number of
advantages over previously published routes to constructing the central benzimidazole
moiety of telmisartan, there was room for significant improvement of this fragment. In order
to establish the proof of concept for a Suzuki based approach to the dibenzimidazole core
of telmisartan, gaining immediate access to the key synthons was of great importance.
Accordingly, the first generation route to the trifluoroborate salt 65 was devised to be
expeditious, but there are multiple factors that would become major deterrents to applying
this chemistry on an industrial scale.
There were a few major areas that were targeted for improvement from the first
generation process. First, both the installation of the boron species and the reduction of the
nitro group require a rather large amount of palladium catalyst, which can be expensive. By
finding alternate transformations the use of palladium could be significantly reduced or
potentially eliminated completely. The other issue involves the selection of pinacol diboron
(81) to introduce the boron species. This synthetic approach greatly improves the atom
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economy of the process. The large pinacol ester is added and subsequently discarded upon
transformation into the trifluoroborate. Moreover, the need to use a large excess (2-5
equivalents) during this step contributes to a significant amount of additional waste.

3.4.1 Reductive cyclization of nitroaniline 83 with butyraldehyde
The first item addressed was the problematic and moderate yielding synthetic
sequenced used to from the benzimidazole component. An alternative route was explored
and provided a more efficient approach to the preparation of the potassium (4-methyl-2propyl-benzimidazol-6-yl) trifluoroborate (65). Aldehydes have been shown to react with onitroaniline species, in the presence of sodium dithionite, to form benzimidazole rings
directly via a reductive cyclization. The reductive cyclization route was explored and
butyraldehyde (41), a less expensive and safer carbonyl compound was used instead of
butyryl chloride (7), which was used in the first generation process. Butyraldehyde (41)
avoids the acylation used previously and is installed via a reductive amination. Secondly,
the expensive palladium on carbon can be replaced by sodium dithionite. Sodium dithionite
is a relatively inexpensive reagent that has been shown to reduce aryl nitro groups to
amines while tolerating a large range of other functional groups. 57
The reductive cyclization was initially performed starting from (4-amino-3-methyl-5nitrophenyl) boronic acid pinacol ester (83). Refluxing this nitroaniline in a 50%
methanol/water mixture and with a large excess of sodium dithionite produced the
benzimidazole 87. In a similar fashion to the first generation process, the pinacol boron was
not isolated, but instead transformed directly to the trifluoroborate to ease purification and
increase amount of product recovered.
This

initial

process

yielded

the

desired

synthon,

potassium

(4-methyl-2-

propylbenzimidazol-6-yl) trifluoroborate (65), with a moderate isolated yield of 60% over two
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steps (Figure 35). Although the yield for this process is very similar to the first generation
process, significant improvements have been realized. Specifically, the removal of one
palladium catalyzed step and the elimination of two unit operations. This two-step process
achieved the same transformation that previously required four chemical steps. However,
the moderate yield still left a significant amount of room for improvement.

Figure 35. Two-step preparation of trifluoroborate 69 from nitroaniline pinacol boron

3.4.2 Proposed route to form benzimidazoles via reductive cyclization
Although, sodium dithionite is capable of reducing nitro groups all the way to amines,
in the case of o-nitroaniline substrates that have been exposed to aldehyde reagents, a
reductive cyclization pathway takes precedence (Figure 36). The process starts by the
amino group of the nitroaniline (89) condensing with aldehyde 41 to the o-nitrophenyl imine
91 through the hemiaminal 90. The nitro group of the newly formed imine 91 is then partially
reduced to the hydroxylamine 92. The hydroxylamine is poised to attack the electrophilic
carbon of the imine, resulting in an intramolecular cyclization to

benzimidazoline 93. This

benzimidazoline

producing

then

undergoes

a

second

benzimidazole 94.
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dehydration,

the

desired

(adapted from Yang D, Fokas D, Li J, Yu L, Baldino CM. Synthesis. 2005. 1, 47-56.)

Figure 36. Proposed route to benzimidazole via reductive cyclization

It is important to point out the importance of the partial reduction of the nitro group.
Sodium dithionite has been shown to reduce nitro groups to amines in the presence of a
strong acid. However, if the nitro group was completely reduced, the product would be in
the wrong oxidation state to reach the required benzimidazole. Additionally, if the sodium
dithionite could reduce the nitro group complete to the amine, it is possible an additional
condensation with unreacted aldehyde could occur.

3.4.3 Reductive cyclization of bromo-nitroaniline 66 with butyraldehyde
Although, the use of sodium dithionite to perform a reductive cyclization on the 4amino-3-methyl-4-nitrophenyl boronic acid pinacol ester (75) did provide some advantages
over the first generation process, the yield for this sequence of reactions was still only
moderate (60%). A modest yield can lead to significant cost increases, as less of the
material is channeled down the desired pathway. One possibility to boost the yield of the
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cyclization sequences, and thus reduce the associated cost, is to perform the boronation
after benzimidazole formation.
Experiments reported earlier described the dehalogenation of the starting material
(4-bromo-2-methyl-6-nitroaniline,

66)

during

the

attempted

palladium

catalyzed

hydrogenation of the nitro group of an acylated derivative (77). However, the use of sodium
dithionite provides a route to a benzimidazole performing the reduction in a manner
compatible with the presence of the halogen58. Applying the reductive cyclization approach
to the brominated nitroaniline 66 provides a convenient and high-yielding one-step route to
benzimidazole formation (Figure 37). This reaction results in the generation of a previously
unavailable intermediate (6-bromo-4-methyl-2-propyl-benzimidazole, 95), which was
isolated from the reaction mixture in a 97% a significant increase in yield over the
analogous reaction with the boronated starting material (83).

Figure 37. Formation of 6-bromo-4-methyl-2-propylbenzimidazole (95)

3.4.4 Palladium catalyzed installation of boronate with pinacol diboron to benzimidazole 95
With bromobenzimidazole 95 now available, a two-step process was used to convert
95 to the precursor target trifluoroborate 65. Initially, pinacol diboron was again used to
install the boron species and was inserted using 5 mol% of PdCl2dppf to catalyze the
reaction. In this case, the pinacol boronate 87 is not isolated or purified and is taken directly
to the trifluoroborate using potassium bifluoride. These two-steps produced the desired
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benzimidazole 65 in a 90% isolated yield from benzimidazole 95 (Figure 38). This improved
process generates the central benzimidazole component in three steps with an overall yield
of 87% from commercially available bromo-nitroaniline 66. This is an improvement of 27%
when compared to the 60% overall yield from the first generation process from the same
starting material.

Figure 38. Two-step preparation of trifluoroborate 65 from
benzimidazole 95 with pinacol diboron

3.4.5 Palladium catalyzed installation of boronic acid with diboronic acid
The reductive cyclization provided a much more efficient route to form the
benzimidazole ring, greatly increasing the yield and eliminating the problematic three step
sequence (amidation, palladium reduction, and cyclization) from the first generation process
to make 65 from bromo-nitroaniline 66. However, the synthetic sequence shown in Figure
38 is high yielding, it still relies on the use of a large excess of pinacol diboron to install the
boron species. This pinacol diboron step has very poor atom economy as well, and it
requires 5 mol% of PdCl2dppf, which is not ideal.
In 2010, Molander reported a method for the use of diboronic acid (B2(OH)4) as a
method to transform aryl chlorides into boronic acid derivatives and trifluoroborates.59

To

achieve this, Molander used 1-2.5 mol% of a palladium precatalyst developed by Buchwald
in

2008,60

along

with

the

expensive
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ligand

2-dicyclohexylphosphino-2’,4’,6’-

triisopropylbiphenyl (XPhos). The palladium precatalyst then reacts with a diboronic acid
ethyl ester formed in situ from the reaction of the diboronic acid and the ethanol used as a
solvent. This diboronic acid ester reacts in a similar manner to the pinacol diboron and
ultimately leads to the installation of the boron species. Without isolation the boronic acid
ethyl ester can be transformed directly to a trifluoroborate or other boronic acid derivative
(Figure 39).

Figure 39. Molander preparation of trifluoroborates from aryl chlorides

Molander’s approach using diboronic acid provides a more atom economical route to
install the boron species to 6-bromo-4-methyl-2-propylbenzimidazole (95) with the potential
to also decrease the amount of palladium needed to catalyze the reaction, thereby
increasing reaction efficiency. Since bromides are typically more active than chlorides
towards Suzuki reactions, efforts were focused on avoiding the inconvenient precatalyst
and expensive ligand in favor of other catalyst and ligand systems (Table 6). While
maintaining a similar catalyst loading (2 mol%) it was found that PdCl2dppf with XPhos
provided complete conversion to the boronic acid (96) in a short time (entry 3).
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Table 6. Installation of boronic acid with diboronic acid and
6-bromo-4-methyl-6-propylbenzimidazole 95

entrya

catalyst

ligand

time

96b

1

2 mol% Pd(OAc)2

XPhos

15 h

23

2

2 mol% PdCl2dppf

none

15 h

75

3

2 mol% PdCl2dppf

XPhos

5h

100 (93%)c

4

2 mol% PdCl2dppf

PPh3

5h

90 (83%)

5

2 mol% Pd2dba3

PPh3

15 h

85

6

2 mol% PdCl2(PPh3)2

none

15 h

78

7

2 mol% PdCl2(PPh3)2

XPhos

5h

100

8

2 mol% PdCl2(PPh3)2

PPh3

15 h

80

a

95 (100 mg,0.40 mmol), B2(OH)4 (106 mg, 1.2 mmol), KOAc (116 mg, 1.2 mg)
Relative peak area determined by HPLC
c
Values in parentheses represent isolated yield after transformation to trifluoroborate
b

When carried forward to the trifluoroborate, this system produced an isolated yield of
93%. This was promising, but ultimately still utilized a more expensive palladium catalyst
and ligand. Using the same catalyst (PdCl2dppf) and a much less expensive ligand
(triphenyl phosphine, PPh3) the reaction still proceeded, but with a lower isolated yield of
83% when carried on to the trifluoroborate (table 6, entry 4). Next, a less expensive
alternative to PdCl2dppf was tested. Bis(triphenylphosphine)palladium (II) dichloride
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(PdCl2(PPh3)2) provided complete conversion to the boronic acid when paired with XPhos
(entry 7) and an 80% conversion when used with PPh3 (entry 8). Despite the lower
conversion for the PdCl2(PPh3)2/PPh3 conditions, they still provided a more economical
process to prepare the trifluoroborate and were further examined in more detail.

3.4.6 Dosing experiments and optimization of boronation reaction
The PdCl2(PPh3)2/PPh3 system was then monitored over time. In initial experiments,
both 1 mol% and 2 mol% catalyst loading levels were tested, and in both cases the catalyst
appeared to be deactivated after only 8 hours. In an attempt to drive the reaction even
further, an additional dose of catalyst and ligand was added to each reaction and a
subsequent modest increase in product formed was observed (Figure 40).

1

3 mol%

0.9
0.8
2 mol%

0.7

R.P.A.

0.6
0.5
1 mol%
0.4
0.3
0.2
Additional dose of catalyst
0.1
0
0

10

20

30
Time (h)

40

50

Figure 40. Dosing experiments of boronation reaction with diboronic acid
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Even after the second dose of catalyst the 1 mol% reaction (now containing a total of
2 mol% catalyst), showed a lower conversion than the reaction than originally was charged
with 2 mol% did after only 8 hours (Table 7, entries 2 and 3). It was also noted that
increased palladium loading at the beginning of the reaction resulted in a significant
increase in conversion. Finally, that information was used to leverage the tendency for the
reaction to occur more rapidly earlier in the reaction. Initial palladium loading was increased
to 3 mol% and an even higher conversion was observed (Figure 40, top line). After 8 hours
the 3 mol% reaction produced the boronic acid intermediate (96) with a conversion of 93%
and a 90% isolated yield when carried forward to the trifluoroborate salt (Table 7, entry 5).

Table 7. Effect of catalyst loading on installation of boronation of 95 with diboronic acid

entrya

catalyst

ligand

time

96b

1

1 mol% PdCl2(PPh3)2

PPh3

8h

50

2

1 mol% PdCl2(PPh3)2

PPh3

48 hd

59

3

2 mol% PdCl2(PPh3)2

PPh3

8h

77

4

2 mol% PdCl2(PPh3)2

PPh3

48 hd

90

5

3 mol% PdCl2(PPh3)2

PPh3

8h

93 (90%)c

a

95 (100 mg,0.40 mmol), B2(OH)4 (106 mg, 1.2 mmol), KOAc (116 mg, 1.2 mg)
Relative peak area determined by HPLC
c
Values in parentheses represent isolated yield after transformation to trifluoroborate
d
Second dose of catalyst added at 24 h.
b
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The 3 mol%, the PdCl2(PPh3)2/PPh3 system (Figure 41), despite a slightly
higher catalyst loading and slightly lower yield, still provides a more economical approach to
prepare

potassium

(4-methyl-2-propylbeznimidazol-6-yl)

trifluoroborate

(65).

When

compared to the boronation reaction with pinacol diboron, diboronic acid provides a more
atom economical boron substitute while requiring less of a cheaper catalyst (3 mol%
PdCl2(PPh3)2

vs.

5

mol%

PdCl2dppf)

to

produce

potassium

(4-methyl-2-propyl-

benzimidazol-6-yl) trifluoroborate (65) with overall yield of 90% over two transformations.

Figure 41. Two-step preparation of trifluoroborate 69 from
benzimidazole 95 with diboronic acid

3.4.7 Formation of benzimidazole 65 from 66 with no isolated intermediates
Again, trifluoroborate 65 was formed directly from the bromo-nitroaniline 66 without
any intermediate isolation. This new process completes all three steps (reductive
cyclization, boronic acid installation and conversion to trifluoroborate) to produce the
desired benzimidazole component (65) and can easily be isolated in pure form. This
telescoped strategy leads to an improved isolated yield of 90% (Figure 42). This new route
addresses the major issues associated with the first generation cyclization while greatly
increasing the yield.
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Figure 42. Three-step preparation of trifluoroborate 65 from bromo-nitroaniline 66.
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CHAPTER IV
PREPARATION OF TELMISARTAN

4.1

Background
Most of the previously reported telmisartan syntheses prepared telmisartan by

cyclization of each benzimidazole sequentially, followed by the installation of the biphenyl
group. This strategy suffers from significant impurities often related to the formation of the
benzimidazole components.61 The highly selective Suzuki cross-coupling reaction
envisioned provides an alternative as the key step in our total synthesis. This approach is
highly tolerant of a wide variety of functional groups, giving larger flexibility throughout the
synthesis with the potential to significantly reduce impurities.

4.1.1 Impurities associated with traditional approach
The impurities from the original approach are most often associated with the
problematic condensation between 4-methyl-2-propylbenzimidazole-6-carboxylic acid (13)
and N-methyl-o-phenylene diamine (9). This reaction is run at elevated temperatures for an
extended period of time in PPA (Figure 43). The condensation produces the functionalized
benzimidazole (10), but the harsh conditions can lead to many difficult-to-remove impurities.
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Figure 43. Problematic condensation reaction from Ries synthesis

As the impurities are difficult to remove, they are often carried forward to
downstream steps. Most of the impurities in the final telmisartan product are associated with
this condensation (Figure 44). Because the reaction only produces a 64% yield, there is
likely a small amount of unreacted 13, that if present during the subsequent alkylation and
hydrolysis steps could produce 1-((2’-carboxy-[1,1’-biphenyl]-4-yl) methyl)-4-methyl-2propylbenzimidazole-6-carboxylic acid (98). However, there are a lot of impurities that stem
from

the

N-(2-aminophenyl)-4-methyl-2-propylbenzimidazole-6-carboxamide

(97),

an

impurity that likely arises from the presence of unmethylated o-phenylene diamine that does
not completely undergo cyclization. The impurity 97 can also lead to 7’-methyl-2’-propyl2,6’-dibenzimidazole (99) upon cyclization of the unalkylated o-aminophenyl amide. Similar
to 98, dibenzimidazole 100 can be produced by subsequent alkylation and hydrolysis
leading to addition of the biphenyl moiety at both the 1- and 1’-position of the
dibenzimidazole.
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Figure 44. Common impurities from Ries Synthesis

4.1.2 Previous attempt at synthesis of telmisartan via simultaneous ring closures
Prior to exploring the Suzuki reaction, an alternative route to form the
dibenzimidazole was investigated (Figure 45). The goal of this synthesis was to improve
upon the efficiency of the original approach by simultaneously forming both benzimidazole
rings. This scheme utilizes a similar approach to the Wen patent synthesis, but varied the
method used to form the diamide species (43) and perform the concurrent ring closures.
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Figure 45. Formation of dibenzimidazole 10 via simultaneous ring closures

Starting from commercially available methyl-4-butyramido-3-methyl-5-nitrobenzoate
(12), the methyl ester was hydrolyzed using sodium hydroxide producing 4-butyramido-3methyl-5-nitrobenzoic acid (17) with a yield of 78%. Instead of using an expensive coupling
agent to form the amide with the N-methyl-o-phenylene diamine (9), butyl chloroformate
was used to form the mixed anhydride 101 providing a moderate yield of 65%. The isolated
anhydride was then condensed with 9 to produce the nitro diamide 43 with a low yield of
42%. However, with the nitro diamide structure formed, the penultimate reduction of the
nitro group (to produce 102) and subsequent cyclization both proceeded with reasonable
yields (83% and 90%, respectively). This work showed some promise as a viable route to
produce the common dibenzimidazole intermediate (10) with the final steps reacting in high
yields. Significant improvements of early reaction steps would be required in order to make
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the approach a more realistic alternative. As it stands, this process produces the
dibenzimidazole intermediate 10 with only a 16% yield over 5 steps.

4.2

Suzuki cross-coupling reactions
A major component of the approach from the proposed retrosynthetic analysis relies

on a Suzuki-Miyaura cross-coupling reaction to form the dibenzimidazole linker. The Suzuki
reaction has found utility across a wide range of chemistry, from use in polymers62,
agriculture63, pharmaceuticals64 and even the synthesis of complex natural products65.
Many advantages are also associated with the Suzuki reaction over other cross-coupling
reactions.66 These reactions typically are performed using milder conditions while using less
toxic reagents. Additionally, boronic acid derivatives provide easily removable inorganic
byproducts. Most importantly, the Suzuki reaction can tolerate most functional groups and
even remain active in the presence of water.

4.2.1 Suzuki cross-coupling catalytic mechanism
The Suzuki-Miyaura reaction proceeds through a catalytic cycle containing four
major steps that ultimately lead to the formation of a new carbon-carbon bond (Figure 46).
The first step is the oxidative addition of an aryl halide to a palladium (0) complex (103).
Palladium insertion occurs between the aryl group and the halide substituent forming a
palladium (II) species (104). At this point, the palladium complex under goes a base
mediated metathesis replacing the halide with the anion of the base (105).
Simultaneously, the organoboron 107 must first be transformed into the
corresponding organoborate (108) by the addition another equivalent of the base. This
activated boron compound can then undergo transmetallation placing both aryl species on
the same palladium

atom

(106) releasing the
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inorganic byproduct

109.

After

transmetallation the palladium (II) complex 106 then undergoes reductive elimination,
releasing the newly formed biaryl product and regenerating a palladium (0) complex that
can proceed to catalyze the formation of other carbon-carbon bonds in the reaction mixture.

Figure 46. Suzuki cross-coupling reaction mechanism

4.2.2 Suzuki proof of concept reactions with 2-bromo-1-methylbenzimdazole
Prior to the work done on this project, a Suzuki reaction had not ever been reported
that includes the reaction of a bromide at the 2-position of a benzimidazole. Before
exploring the more advanced chemical systems, a few proof of concept reactions were
completed to demonstrate the viability of 2-bromo-1-methylbenzimidazole (54) as a
potential candidate for the preparation telmisartan. The first reaction completed was the
coupling of halide 54 with the phenyl boronic acid (110) (Figure 47). This reaction, catalyzed
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by palladium acetate with a triphenyl phosphine ligand, led to a relative conversion of 98%
to the desired 1-methyl-2-phenylbenzimidazole (111).

Figure 47. Suzuki reaction of 2-bromo-1-methylbenzimidazole and phenyl boronic acid

The successful coupling at the 2-position of benzimidazole 54 with the simple
boronic acid was very promising. The same reaction was attempted with a more
functionalized system (Figure 48). Commercially available 4-amino-3-nitrophenyl boronic
acid pinacol ester (112) was chosen as the next coupling partner due to its similarity with
the nitroaniline target (83) described earlier. The reaction proceeded to produce the desired
2-(4-amino-3-nitrophenyl)-1-methylbenzimidazole (113) with high relative conversion.

Figure 48. Suzuki reaction between benzimidazole 54 and nitroaniline 112

With the promising results in hand from the proof of concept studies, the strategy
was applied to authentic telmisartan precursors. One route envisioned involved the
formation of 2-(4-amino-3-methyl-5-nitrophenyl)-1-methylbenzimidazole (40) by coupling
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benzimidazole 54 with (4-amino-3-methyl-5-nitrophenyl) boronic acid pinacol ester (83)
(Figure 49). When this was attempted, the reaction led to a reasonable relative conversion
(80%) to the desired coupling product 40 proving that the Suzuki is a viable method to form
the carbon-carbon linker between the two dibenzimidazoles of telmisartan.

Figure 49. Suzuki reaction of benzimidazole 54 and nitroaniline 83.

It is presumed that the nitroaniline 40 could be transformed to the dibenzimidazole,
carried forward through any of the previously described methods for the formation of
benzimidazoles from o-nitroanilines. However, due to the moderate conversion and the
problems associated with the cyclization method historically used to construct telmisartan
(the amidation, reduction and acid cyclization), this route was not explored further in favor of
more promising avenues.

4.2.3 Suzuki reaction of benzimidazoles 54 and 83
The next route attempted involved performing a Suzuki reaction with the two
benzimidazoles components already formed. This strategy would minimize the impact of
any yield loss during benzimidazole cyclization on the cost associated with the palladium
catalyst required for the Suzuki reaction. This route also targets the primary
dibenzimidazole intermediate (10), which serves as the starting material for the commercial
process. Dibenzimidazole 10 is formed by coupling 2-bromo-1-methylbenzimidazole (54)
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and 4-methyl-2-propylbenzimidazol-6-yl boronic acid pinacol ester (83) (Figure 50).
However, this reaction only produced the desired benzimidazole (10) with relatively low
conversion, and a significant amount of byproduct was observed.

Figure 50. Suzuki reaction of benzimidazoles 54 and 83

When investigated further mass analysis led to the conclusion that the reaction was
also resulting in a 1,2’-dibenzimidazole 114 (Figure 51). It is proposed that the bromide of
54 undergoes a nucleophilic substitution with the deprotonated nitrogen at the 1-position of
benzimidazole 87. Left unprotected, the nucleophilic nitrogen of 87 is susceptible to this
type of reactivity. These observations were leveraged later in the process for the installation
of the biphenyl moiety, achieved via nucleophilic substitution of a biphenyl halide.

Figure 51. Proposed byproduct from Suzuki to form dibenzimidazole 10
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4.3

First generation preparation of telmisartan with biphenyl carbonitrile

4.3.1 Alkylation to install biphenyl carbonitrile component
Instead of using a protecting group it was hypothesized that installing the biphenyl
moiety prior to the Suzuki reaction would preclude the unwanted byproduct. The biphenyl
group would eliminate the presence of the removable proton at the 1-position of the central
benzimidazole, without requiring additional protection and deprotection reactions to perform
the Suzuki reaction. In order, to proceed in the most expeditious manner possible, the
installation was performed using a strategy similar to the current commercial process.
Prior to introducing the biphenyl halide, potassium tert-butoxide (KOtBu is used to
deprotonate the 1-postion of potassium (4-methyl-2-propylbenzimidazol-6-yl) trifluoroborate
(65). The biphenyl is installed using 4’-(bromomethyl)-[1,1’-biphenyl]-2-carbonitrile (41). The
N-alkylation reaction occurs at room temperature and produces potassium (1-((2’-cyano[1,1’-biphenyl]-4-yl)-methyl)-4-methyl-2-propylbenzimidazol-6-yl) trifluoroborate (115). This
process provides the desired product (115) with an isolated yield of 90% (Figure 52).
Notably, it was found to be necessary to pretreat the benzimidazole 65 with the base in
order to avoid the formation of unwanted Williamson ether byproducts.

Figure 52. Alkylation of benzimidazole 65 with biphenyl nitrile 41
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4.3.2 Suzuki reaction of benzimidazoles 54 and 115
With the biphenyl benzimidazole and trifluoroborate components in place, compound
115 was then successfully coupled with 2-bromo-1-methylbenzimidazole (54). This was the
first case when the Suzuki reaction successfully formed the dibenzimidazole linker without
any major complications. Using PdCl2dppf, the two benzimidazoles were combined
producing the nitrile of telmisartan (46) in high yield (Figure 53). In only a short period of
time (10 minutes), under microwave irradiation at 120oC the reaction achieved a 91%
isolated yield.

Figure 53. Suzuki reaction of benzimidazoles 54 and 115

4.3.3 Hydrolysis of nitrile 115 to form telmisartan
Finally, with the nitrile of telmisartan (46) in hand there remained only one
transformation to complete the synthesis utilizing the new disconnection approach featuring
the Suzuki reaction between two different functionalized benzimidazoles. This final step was
the hydrolysis of the nitrile to produce the carboxylic acid (Figure 54). Using the method
described in the commercial process, the nitrile (46) undergoes hydrolysis using KOH and
150oC for 15 hours. After acidification with AcOH, this yielded telmisartan (1) with an
isolated yield of 60%.
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Figure 54. Nitrile hydrolysis to form telmisartan

4.3.4 First generation three-step preparation of telmisartan using biphenyl carbonitrile
Although, this step used in the commercial process, there are several notable
disadvantages. In the experiments performed, the reaction did not proceed all the way to
the carboxylic acid. A significant amount of the amide (an intermediate in the hydrolysis)
was present in the final reaction mixture and was difficult to remove completely from the
product. This process also relies on high temperatures and long reaction times. These two
aspects are unfavorable when considering the ultimate goal of completing the synthesis of
telmisartan in flow. However, this method constituted the first time that telmisartan (1) was
produced using a Suzuki reaction to form the dibenzimidazole linker. This approach
provided an overall yield of 49% from the benzimidazole precursors (Figure 55).
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Figure 55. Three-step preparation of telmisartan using nitrile

4.4

Second generation preparation of telmisartan with biphenyl methyl ester

4.4.1 One-pot alkylation and hydrolysis using methyl ester
With the previous approach, the Suzuki reaction was shown to be a valid strategy for
assembling telmisartan; however, the use of the nitrile introduced some issues that could be
mitigated by finding an alternative biphenyl component. Instead of the nitrile, the analogous
methyl ester, methyl-4’-(bromomethyl)-[1,1’-biphenyl]-2-carboxylate (14), was elected as an
alternative with the potential for resolving the issues related to the hydrolysis to form the
final carboxylic acid. Again, the N-alkylation was performed using potassium tert-butoxide
as a base. The alkylation of benzimidazole 65 with the biphenyl 14 was found to proceed
quickly, producing the methyl ester (116) with excellent conversion.
It was also found that, if the reaction was allowed to stir for an extended time, the
carboxylic acid would start to appear in the reaction mixture. With even a small amount of
water present in the solvent, the potassium tert-butoxide can react to form potassium
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hydroxide, which can in turn hydrolyze the methyl ester of 116. Instead of developing a
method to discourage the formation of the carboxylic acid, the direct alkylation product was
not isolated but rather a solution of aqueous potassium hydroxide was introduced to
facilitate hydrolysis (Figure 56). These two telescoped steps provided the desired carboxylic
acid (117) in a high yield of 93%. This process constitutes a high-yielding and streamlined
route to the desired carboxylic acid.

Figure 56. Two-step telescoped alkylation and hydrolysis to form benzimidazole 117

4.4.2 Suzuki reaction of benzimidazole 54 and 117 to produce telmisartan
Finally, with the biphenyl moiety introduced and the hydrolysis complete, the final
coupling reaction of bromide 54 and trifluoroborate 117 was the only remaining step to be
explored. In order optimize the yield and efficiency of the process, a number of reactions
were run. A factorial design of experiment (DOE) was undertaken to identify the set of
reaction parameters that would maximize yield while minimizing catalyst loading. The other
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two factors tested were temperature and microwave irradiation time (Table 8). Using
PdCl2dppf as the catalyst the reactions were run in 50% ethanol solution with KOH as the
base.
Table 8. Microwave assisted DOE of Suzuki cross-coupling to form telmisartan

a

entrya

catalyst loading (mol%)

conditions

1b

1

2

80°C, 5 min.

17

2

10

80°C, 5 min.

56

3

2

150°C, 5 min.

66

4

10

150°C, 5 min.

91

5

5

120°C, 10 min.

85

6

2

80°C, 15 min.

27

7

10

80°C, 15 min.

72

8

2

150°C, 15 min.

76

9

10

150°C, 15 min.

92

10

2

150°C, 30 min.

89

11

10

150°C, 30 min.

95

12

5

150°C, 30 min.

88

13

5

120°C, 30 min.

82

b

54 (0.19 mmol), 117 (0.20 mmol), 4 mL H2O/EtOH (1:1 mixture). Isolated yield
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As expected, it was found that all three had a direct correlation with the yield of the
reaction (Figure 57). The reaction with highest catalyst loading tested (10 mol%) produced
the best yield (95%) when reacted at 150oC for 30 minutes under microwave irradiation
(entry 11). However, using the high catalyst loading is not the most economical approach
despite the highest yield. Lowering the catalyst loading all the way down to 2 mol% (entry
10) the reaction still produced a high yield of 89%. The significant decrease in catalyst
loading only led to a small decrease in yield, making it a more favorable route when taking
cost considerations into account.

Figure 57. DOE of Suzuki cross-coupling to form telmisartan

With the microwave reaction conditions well established, the second set of reactions
explored different palladium catalysts and ligands commonly used for the Suzuki cross-
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coupling reaction (Table 9). All the catalysts tested produced reasonable yields above 60%.
In this case the catalyst used for the DOE provided the best yield of 89% (entry 1).

Table 9. Catalyst screen of Suzuki cross-coupling to form telmisartan

a

entrya

catalyst

ligand

conditions

1b

1

2 mol% PdCl2dppf

n/a

150°C, 30 min.

89

2

2 mol% PdCl2(PPh3)

n/a

150°C, 30 min.

78

3

2 mol% Pd2(dba)3

n/a

150°C, 30 min.

68

4

2 mol% Pd(OAc)2

6 mol% PPh3

150°C, 30 min.

76

5

2 mol% Pd(OAc)2

6 mol% XPhos

150°C, 30 min.

62

b

54 (0.19 mmol), 117 (0.20 mmol), 4 mL H2O/EtOH (1:1 mixture). Isolated yield

With the optimum catalyst and reaction conditions determined utilizing microwave
technology, conditions were explored to determine feasibility under conventional heating
conditions (Table 10). However, with the ethanol/water solvent system the reflux
temperature is around 80oC which is significantly lower than temperatures achieved in the
sealed tube of the microwave reactor. From the DOE it was found that the higher
temperatures lead to much improved yields. Even when the conventional system ran for a
much longer period of time (15 h) it produced low yields. The 2 mol% reaction produced
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only a 36% yield (entry 1). The 10 mol% reaction increased the yield up to 55% (entry 2),
however this result was still suboptimal when compared to the 89% and 95% yields from the
respective microwave reactions (entries 3 and 4). It is anticipated that, in a pressurized
system that could reach the elevated temperatures, conventional heating would produce
higher yields than observed with atmospheric reflux conditions.

Table 10. Comparing conventional heating to microwave heating

a

entrya

catalyst

conditions

1b

1

2

reflux, 15 h

36

2

10

reflux, 15 h

55

3

2

μw 150oC, 30 min

89

4

10

μw 150oC, 30 min

95

b

54 (0.19 mmol), 117 (0.20 mmol), 4 mL H2O/EtOH (1:1 mixture). Isolated yield

4.4.3 Second generation three-step preparation of telmisartan
This approach, based on a key disconnection between intact benzimidazoles,
exploits a Suzuki cross-coupling reaction to establish a concise, convergent synthesis and
high yielding synthesis of telmisartan. This process remedies the difficult hydrolysis of the
nitrile and replaces it with a very simple de-esterification of the methyl ester, while still
providing a route that still allows for the highly reactive Suzuki reaction. Using the optimized
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Suzuki conditions the overall yield for the three-step preparation of telmisartan is 83%
(Figure 58). The overall yield for the entire process, when accounting for the preparation of
the precursor from 4-bromo-2-methyl-6-nitroaniline (66), is 74% which great improves on
even the most recently reported syntheses of telmisartan.

Figure 58. Second generation three-step preparation of telmisartan
using biphenyl methyl ester

4.4.4 Palladium nanoparticles on graphene catalyzed Suzuki cross-coupling reaction to
form telmisartan
In related work within the research group, palladium nanoparticles supported on
graphene (Pd/G) have been developed in house.67 This catalyst system demonstrates
remarkable activity and recyclability in a wide range of Suzuki cross-coupling reactions.
These nanoparticles have an average particle size of 7-9 nanometers (Figure 59) and in
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some cases have reported turnover frequencies as high as 108,000 h-1 with a turnover
number of 9000.

Figure 59. TEM of palladium nanoparticles on graphene

This catalyst system was evaluated for use in the key step of the telmisartan
synthesis, in anticipation of conversion to a continuous process. Preliminary experiments
using just 2 mol% of Pd/G led to a yield of 76% (Table 11, entry 1). In addition to the
reasonable yield, the supported palladium nanoparticles demonstrated the ability to be
recycled. After being removed from the initial reaction solution, the recovered catalyst
successfully produced telmisartan in two subsequent reactions producing yields of 68% and
62%, respectively (entries 2 and 3). However, one problem associated with the use of the
solid supported palladium nanoparticles is an increase in debromination of the starting
material (54).
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Table 11. Recycling experiments for palladium on graphene nanoparticles

a

entry

catalyst recycles

conditions

1

1

0

μw 150oC, 20 min

76

2

1

μw 150oC, 20 min

68

3

2

μw 150oC, 20 min

62

b

54 (0.19 mmol), 117 (0.20 mmol), 4 mL H2O/EtOH (1:1 mixture). Isolated yield

A common problem associated with the use of palladium catalyzed reactions for API
synthesis, is the presence of small amounts of toxic metals contaminating the final product.
One advantage to the use of palladium nanoparticles on a solid support is that the reaction
mixture is heterogeneous, allowing for the catalyst to be removed by simple filtration which
can minimize palladium content after purification. When compared to the isolated product
from the homogeneous catalyst system (PdCl2dppf), the Pd/G had a significantly lower
amount of palladium. When analyzed by ICP the Pd/G only had 27 ppm of palladium in the
final product (Table 12, entry 2). This value is almost four times lower than the 105 ppm of
palladium in the product from the homogeneous system (entry 1).
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Table 12. Palladium contamination comparison in telmisartan

a

entry

catalyst

Palladium content in producta

1

PdCl2dppf

105 ppm

2

Pd/G

27 ppm

Determined by ICP-OES.
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CHAPTER V
CONTINUOUS PREPARATION OF TELMISARTAN
5
5.1 Background
With the goal of streamlining the total synthesis of telmisartan, an ideal scenario
would be to eliminate the need for isolation of intermediates between reactions. The need
for intermediate purification can greatly increase both waste and cost associated with a
chemical process. Furthermore, adapting a chemical process to a continuous operation
presents significant advantages to the traditional batch approach. However, additional
considerations must be made when designing a continuous chemical strategy.
Continuous reactors have been used for a long time in industrial settings, but have
only recently been utilized on a lab scale.68 These flow reactors typically utilize small
channels or tubing to perform more efficient chemical transformations. This elongated
reaction space provides a large surface to volume ratio69, allowing for improved heat
transfer and component mixing throughout the reaction mixture.70 These more efficient
conditions provide lower variation in product purity when compared to conventional batch
systems. Flow reactors also provide a more controlled environment for safer use of highly
reactive materials or intermediates by reducing the amount of material being generated at a
single point throughout the reaction.71 Finally, flow systems provide a more straightforward
progression to increase production. A single reactor could be run for a longer time or more
reactors could be added and run in parallel.
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Figure 60. Example of flow chemistry set-up

In order for a process to be a good potential candidate for flow chemistry there are a
few additional aspects to be considered. The most important is the use of compatible
components throughout the entire process, including the solvent system. Byproducts
produced in the early stage should not interfere with the reactivity of downstream steps.
Additionally, finding a single solvent or mixture of solvents that are compatible throughout
the process eliminates the need for unnecessary solvent exchanges. In a similar manner,
reaction conditions should be identified to perform the chemistry quickly and in high yield.
Any unreacted starting materials can be carried forward, potentially leading to undesired
byproducts or additional complications downstream. Finally, solubility throughout the system
is a major concern. Precipitates or insoluble reactants could potentially clog the system
causing significant problems and ultimately leading to the failure of the system. However,
specific devices have been developed that can handle slurries and significant solid
formation in flow, and some reactors provide a method to immobilize the insoluble
components in a packed bed or similar system.
The batch process described in Chapter IV is an excellent candidate for continuous
chemical processing. Starting from the synthons identified in the retrosynthetic analysis, all
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three transformations to form telmisartan are high yielding reactions, can be performed
quickly or under mild conditions and all three are run under basic conditions. These three
features make conversion to a continuous process very promising, but the batch process is
not directly transferable to flow in its current state. Two major areas of consideration are
compatible solvents and handling solids.

5.2

Development of continuous process for preparation of telmisartan

5.2.1 Solvent compatibility studies
The first aim in the transition from batch to flow is to find a new solvent system that is
compatible with all three steps. Due to the need to run the reactions at elevated
temperatures to facilitate quicker reaction times, solvents with high boiling points were
explored. These solvents were also chosen for their reputation of having good solubility
properties.

The

four

solvents

tested

were

DMSO,

dimethylacetamide

(DMA),

dimethylformamide (DMF) and N-methylpyrrolidone (NMP). The first set of experiments ran
were performing the alkylation and hydrolysis in one-pot using aqueous KOH as the base to
facilitate the nucleophilic substitution and the saponification. The reactions were heated in a
microwave and provided interesting results (Table 13). All four solvents provided good
conversion to the carboxylic acid (117). DMSO and NMP showed the best conversion to
desired product (entries 1 and 4) with 91% and 94%.
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Table 13. One-pot alkylation and hydrolysis to form benzimidazole 117

a
b

entrya

solvent

117b

116b

1

DMSO

91

0

2

DMF

89

0

3

DMA

87

0

4

NMP

94

2

65 (100 mg, 0.36 mmol), 14 (109 mg, 0.36 mmol), KOH (100 mg, 1.8 mmol)
Relative conversion determined by HPLC

The second round of experiments involved screening the compatibility of the Pd/G
catalyst with the different solvents from above. In this case, it was found that the presence
of water greatly increased the reactivity of the catalyst and that the presence of certain
solvents greatly decreased the catalytic activity. A model Suzuki reaction between
bromobenzene (118) and phenyl boronic acid (110) was used to test the activity of the
catalyst in the four solvents mixed with water (Table 14). The DMA/H2O system (entry 3)
provided complete conversion to the desired biphenyl (119), however, the product was
found to form a significant amount of precipitate which is not ideal for flow chemistry. The
NMP reaction gave excellent conversion as well (entry 4), with a 94% conversion to the final
product with no observable solid formation.
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Table 14. Solvent compatibility study of Pd/G catalyst

a
b

entrya

solvent

119b

precipitate formed

1

DMSO/EtOH/H2O

45

no

2

DMF/H2O

84

no

3

DMA/H2O

100

yes

4

NMP/H2O

94

no

118 (50 μL, 0.48 mmol), 110 (64 mg, 0.53 mmol), K2CO3 (198 mg, 1.4 mmol), Pd/G (2.5 mg, 2.4 μmol).
Conversions determined by GC-MS.

5.2.2 Three-step one-pot preparation of telmisartan
Based on the preliminary experiments, NMP was chosen for its high reactivity in both
systems and to avoid precipitate formation. With a solvent system targeted, the next aspect
to be examined was the compatibility of all three steps with no isolation of intermediates. To
test this concept, all three reactions were tested in a one-pot reaction using microwave
heating to simulate flow conditions (Figure 61). This telescoped reaction sequence
produced a 77% isolated yield of telmisartan without any major byproducts or problematic
side reactions.
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Figure 61. Three-step one-pot synthesis of telmisartan

5.2.3 Continuous alkylation and hydrolysis to form benzimidazole 120
The preliminary work ensured that all reagents and solvents are compatible
throughout the process and would not interfere with downstream reactivity. These
observations reinforced the notion that, with minor modifications, this synthetic approach to
telmisartan is an ideal candidate for conversion to flow.

First, the alkylation and de-

esterification steps were performed in a Vapourtec E-series system with two 10 mL PFA
reactor coils (Figure 62). In the first reaction stream, benzimidazole 65 was premixed with
potassium tert-butoxide in NMP. This premixing allows for the deprotonation at the 1position of the benzimidazole. This deprotonation serves two purposes: it improves the
solubility of the trifluoroborate salt and helps to avoid the formation of unwanted Williamson
ether byproducts.
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Figure 62. Vapourtec E-series

The second reaction stream contained a solution of bromide (14) in NMP. The
solutions streams were mixed and fed into the first reactor coil. The first reactor coil was
heated to 100oC and required an estimated residence time of approximately 20 minutes. A
molar excess of potassium hydroxide in water was added to the outlet from the first coil,
which was then introduced into a second reactor 10 mL PFA reactor coil. This combined
mixture was heated in the second coil at 120oC with an estimated residence time of 10
minutes. The pressure of the entire system was maintained between 4 and 5 bar to prevent
bubbles from forming within the reactor coils. These two chemical transformations yielded a
conversion of 97% to the alkylated benzimidazole 120 (Figure 63).
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Figure 63. Flow schematic for alkylation and hydrolysis

5.2.4 Continuous Suzuki reaction to form telmisartan
With the first two continuous transformations complete, efforts were directed towards
the development of continuous conditions for the Suzuki cross-coupling reaction. A
commercially available silica supported palladium (Siliacat® DPP-Pd, Figure 64) was used
to carry out the reaction. The catalyst has a diphenyl phosphine linked to the silica via a
short alkyl chain and has a typical particle size from 60-150 μm. This catalyst was available
in large enough quantities to allow for adequate experimentation and provided high
conversions in test reactions completed under conventional microwave conditions.

90

Figure 64. Ligand structure and TEM image of Siliacat® DPP-Pd catalyst

The Suzuki reaction was performed in a ThalesNano X-cube flow reactor (Figure
65). A packed bed of Siliacat® DPP-Pd was established by loading the catalyst into a
cartridge fitted with frits at both ends. The outlet stream from the previous two steps was
collected in a reservoir and then introduced to a solution containing 1.2 equivalents of 2bromo-1-methylbenzimidazole (54) in a 1:1 NMP/H2O solution. Optimized conditions were
established when the catalyst bed was heated to 180oC and the reaction mixture was
passed through the column at a flow rate of 0.1 mL/min maintaining the pressure at 30-40
bar. The estimated residence time under these conditions was less than 5 min. When the
final product was collected and isolated, this continuous process provided 1 with an overall
yield of 86% over three chemical steps (Figure 66).
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Figure 65. Thalesnano X-cube

Figure 66. Flow schematic for Suzuki reaction to form telmisartan
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This three step process marks the first flow-based synthesis of telmisartan to be
reported in the literature72 (Figure 67). It employs a highly efficient and convergent strategy
that requires no intermediate purifications or solvent exchanges. The process features a
Suzuki cross-coupling reaction catalyzed by a solid supported palladium catalyst in a
packed column and produces an overall yield of 86% over three chemical steps. This
continuous approach represents a significant improvement over existing methods that
require numerous additional unit operations that add complexity and waste to the overall
process. From a broader perspective, this flow-based method may serve as an example for
the continuous preparation of other active pharmaceutical ingredients with similar
structures.

Figure 67. Flow schematic for three-step continuous preparation of telmisartan
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CHAPTER VI
COMPARISON OF PROCESS OPTIONS
6.1

Process options overview
A direct and efficient preparation of telmisartan has been developed. This concise

and convergent approach assembles the target molecule while featuring a Suzuki crosscoupling reaction to form a new carbon-carbon bond between two differentially
functionalized benzimidazoles. This new strategy was enabled by the development of a
regioselective bromination at the 2-position of 1-methylbenzimidazole (55). The overall
approach has proceeded through various iterations, all based on the same synthetic
approach. The first generation process (Figure 68) was designed in the most expeditious
route possible to test the viability of the Suzuki reaction as a key step. Many improvements
to this route were made in parallel with evaluation of the Suzuki cross-coupling reaction;
these advances were incorporated into the second generation process. Despite being
unoptimized, this first iteration provided telmisartan with a 29% overall yield, a slight
improvement from the 21% reported originally in the Ries synthesis.
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Figure 68. First generation synthesis of telmisartan

After the development of the first generation process, multiple aspects were
identified as areas where significant improvements could be realized. The major areas
targeted led to the development of an improved cyclization process for the central
benzimidazole, a more efficient and atom economical installation of the trifluoroborate and
finding a carboxylic acid derivative that could undergo an easy conversion to the final
product. By addressing all three concerns, a much improved second generation process
was achieved, featuring an improved cyclization, reduced palladium catalyst requirements,
and a more atom economic boron source. This new process provides telmisartan with a
high overall yield of 74% with two fewer unit operations (Figure 69).
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Figure 69. Second generation synthesis of telmisartan

Lastly, the final three steps were successfully converted to a continuous system in a
similarly high-yielding process. After minor modifications of the second generation
synthesis, conditions suitable for flow were established. The continuous synthesis of
telmisartan was achieved by pumping advanced intermediates through two reactor coils and
one packed bed column. This flow process is likely to offer significant improvements over
the current commercial route, producing telmisartan with an 86% isolated yield and
eliminating any need for purification of the intermediate compounds (Figure 70).
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Figure 70. Flow preparation of telmisartan

When comparing this new approach with the original process, it is clear significant
improvements have been made (Table 15). A sizable improvement in overall yield has been
achieved while greatly decreasing the number of unit operations by eliminating the need for
solvent exchanges and the isolation of intermediates.
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First
Generation

Second
Generation

Flow

2

3

4

3

6

8

Original

Linear
steps

1

Starting materials

Process

Entry

Table 15. Telmisartan process comparisons

0

2

4

3

Isolated
intermediates

86%

74%

29%

21%

Overall
yield

CHAPTER VII
EXPERIMENTAL

General Methods
All reactions were carried out under ambient atmosphere, unless otherwise noted.
Microwave reactions were performed using a CEM Discover SP microwave system. The
reagents were purchased from commercial suppliers including Sigma Aldrich, Alfa Aesar,
Fisher Scientific, TCI America or Matrix Scientific, and were used as received. Reactions
were monitored using a Waters 2695 high-performance liquid chromatography equipped
with a Waters 996 Photodiode Array Detector. GC-MS analyses were performed on Agilent
6890 gas chromatograph equipped with an Agilent 5973 mass selective detector. The ESIMass spectra were recorded on a Micromass Waters QTOF-2 mass spectrometer equipped
with a custom built microspray source. Both 1H and

13

C NMR Spectra were acquired on a

Varian Mercury 300 MHz or a Bruker 400 MHz NMR spectrometer using DMSO-d6 or CDCl3
as solvents.
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2-Bromo-1-methylbenzimidazole (54)

1-methylbenzimidazole (55, 5.0 g, 37.8 mmol) and N-bromosuccinimide (62, 20.2 g,
113.5 mmol) were taken up in 200 mL of THF. The solution was put under an atmosphere
of nitrogen and heated at reflux for 1 h. The solvent was removed in rotary evaporator and
the residue was taken up in 20 mL of MeOH. The solid remaining was filtered and
discarded. 100 mL of EtOAc was added to the filtrate producing a white solid. The solid was
filtered and dried providing 2-bromo-1-methylbenzimidazole (54, 7.4 g, 93%) as a white
solid. 1H NMR (DMSO-d6) δ 7.77 (d, 1H), 7.65 (d, 1H), 7.39 (m, 2H), 3.86 (s, 3H);

13

C NMR

(DMSO-d6) δ 138.2, 135.4, 131.5, 124.8, 124.7, 117.0, 112.3, 33.0; HRMS (ESI-QTOF):
m/z Calcd for C8H7N2Br + H+: 210.9871, found: 210.9862.

N-(4-bromo-2-methyl-6-nitrophenyl)butyramide (77)

4-bromo-2-Methyl-6-nitroaniline 66 (1.0 g, 4.33 mmol) and butyryl chloride 7 (1.3 mL,
13.0 mmol) in 20 mL of ClBn were heated at 95oC with a reflux condenser for 5 hours. After
cooling to room temperature 80 mL of hexanes were added and a light yellow precipitate
was formed. The precipitate was filtered and dried producing compound 77 (1.3 g, 82%). 1H
NMR (DMSO-d6) δ 9.85 (s, 1 H), 7.95 (s, 1 H), 7.86 (s, 1 H), 2.3-2.2 (m, 5 H), 1.57 (m, 2 H),
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0.90 (t, 3 H);

13

C NMR (DMSO-d6) δ 171.7, 147.4, 139.5, 137.5, 128.8, 125.0, 118.2, 37.6,

18.8, 18.0, 14.0.

(4-Amino-3-methyl-5-nitrophenyl) boronic acid pinacol ester (83).

4-bromo-2-methyl-6-nitroaniline 66 (5.0 g, 21.6 mmol) and bis(pinacolato)diboron 81
(10.1 g, 43.3 mmol) we placed in a 250 mL flask along with KOAc (6.4 g, 64.9 mmol) and
PdCl2dppf (1.5 g, 2.05 mmol). DMSO (50 mL) was added and the flask evacuated. The
solution heated at 100°C for 5 h. The reaction mixture was cooled followed by the addition
of 200 mL H2O and extraction with EtOAc (3 x 100mL). The organic layer was combined
and concentrated by rotary evaporation and the resulting oil was taken up in hexanes (200
mL). The precipitate that formed was filtered and discarded. The filtrate was evaporated and
the residue was recrystallized in water, then dried to produce 83 (5.7 g, 95%). 1H NMR
(DMSO-d6) δ 8.2 (s, 1H), 7.5 (s, 1H), 7.4 (s, 2H), 2.2 (s, 3H), 1.3 (s, 12H).
(DMSO-d6) δ 147.1, 141.2, 131.5, 131.3, 126.4, 119.1, 84.3, 25.3, 18.4.
Calculated for C13H20O4N2B+: 279.14, found: 279.15.
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13

C NMR

ESI-MS:

(4-Methyl-2-propylbenzimidazol-6-yl) boronic acid pinacol ester (87)

Method A
Butyryl chloride 7 (5.5 mL, 54 mmol) was added to a 250 mL flask containing 4bromo-2-Methyl-6-nitroaniline 66 (5.0 g, 18 mmol) in Chlorobenzene (50 mL). The reaction
mixture was stirred at 95°C for 5 h. The solvent was removed by rotary evaporation. The
residue was taken up in methanol (50 mL) followed by the addition of 10 wt% Pd/C (1.0 g).
The mixture was stirred at room temperature for 15 h under hydrogen balloon. After filtration
through Celite, the filtrate was evaporated by rotary evaporation. The residue was taken up
in acetic acid and refluxed for 1 h. The solvent was removed by rotary evaporation and the
solid was rinsed with ethyl acetate producing (4-Methyl-2-propylbenzimidazol-6-yl) boronic
acid pinacol ester (87, 3.2 g, 60%) as a light brown solid. 1H NMR (DMSO-d6) δ 7.54 (s, 1
H), 7.22 (s, 1 H), 2.76 (t, 2 H), 2.43 (s, 3 H), 1.73 (m, 2 H), 1.23 (s, 12 H), 0.89 (t, 3 H);

13

C

NMR (DMSO-d6) δ 155.8, 128.5, 124.0, 118.7, 83.7, 30.7, 25.1, 21.4, 17.0, 14.1.

Method B
4-bromo-2-Methyl-6-nitrophenyl boronic acid pinacol ester (83) (2.0 g, 7.2 mmol) and
butyraldehyde 41 (1.3 mL, 14.4 mmol) were added to a flask along with sodium dithionite
(7.5 g, 43.2 mmol) and 40 mL of 50% MeOH in H2O. The mixture was stirred at reflux for 5
h. The MeOH was removed by rotary evaporator. An additional 20 mL of H2O was added to
the remaining aqueous solution and was then extracted using DCM (3 x 50 mL). The
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organic layer was removed by rotary evaporation. The resulting solid was rinse with ethyl
acetate producing (4-Methyl-2-propylbenzimidazol-6-yl) boronic acid pinacol ester (87) as a
light brown solid (1.3 g, 60%).

Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65).

Method A
Butyryl chloride 7 (5.5 mL, 54 mmol) was added to a 250 mL flask containing 4bromo-2-Methyl-6-nitroaniline 66 (5.0 g, 18 mmol) in Chlorobenzene (50 mL). The reaction
mixture was stirred at 95°C for 5 h followed by evaporation. The residue was taken up in
methanol (50 mL) followed by the addition of 10 wt% Pd/C (1.0 g). The mixture was stirred
at room temperature for 15 h under hydrogen balloon. After filtration through Celite, the
filtrate was evaporated. The residue was taken up in acetic acid and refluxed for 1 h. After
removing the solvent by rotary evaporation, the residue was taken up in THF (100 mL) and
combined with a solution of potassium bifluoride (7.0 g, 90 mmol) in H 2O (20 mL). The
combined solution was stirred at room temperature for 5 h. Upon removal of THF, the
precipitate was filtered and rinsed using EtOAc, yielding 65 as a white solid (3.9 g, 63%). 1H
NMR (DMSO-d6) δ 7.2 (s, 1H), 7.1 (s, 1H), 2.8 (t, 2H), 2.5 (s, 3H), 1.7 (m, 2H), 0.9 (t, 3H).
13

C NMR (DMSO-d6) δ 152.5, 130.7, 129.3, 121.4, 113.0, 28.5, 21.0, 17.1, 14.0. ESI-MS:

Calculated for C11H14N2BF3K+: 281.08, found: 281.07.
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Method B
4-bromo-2-Methyl-6-nitroaniline (66) (2.0 g, 8.7 mmol) and butyraldehyde 41 (1.6
mL, 17.3 mmol) were added to a flask along with sodium dithionite (7.5 g, 43.2 mmol) and
40 mL of 50% MeOH in H2O. The mixture was stirred at reflux for 5 h. The MeOH was
removed by rotary evaporator. An additional 20 mL of H2O was added to the remaining
aqueous solution and was then extracted using DCM (3 x 50 mL). The organic layer was
concentrated by rotary evaporator and then taken up in 80 mL of EtOH. The solution was
added to a flask containing diboronic acid (2.3 g, 26.0 mmol), KOAc (2.5 g, 26.0 mmol),
PdCl2(PPh3)2 (182 mg, 0.26 mmol) and triphenylphosphine (91 mg, 0.35 mmol). The flask
was then evacuated and placed under nitrogen. The solution was heated at 75 °C for 10 h.
The reaction mixture was cooled, filtered and then concentrated by rotary evaporator
followed by the addition of 80 mL of H2O. The aqueous mixture was then extracted with
EtOAc (3 x 100 mL). The organic layer was combined, concentrated and then the volume
was adjusted to 100 mL by adding more EtOAc. The solution was then combined with a
solution of potassium bifluoride (3.4 g, 43.3 mmol) in H2O. The biphasic mixture was stirred
at room temperature for 5 hours. The precipitate was filtered, rinsed using THF and then
dried, yielding potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65) as a
white solid (2.2 g, 90%).
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Potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate (88).

4-bromo-2-Methyl-6-nitroaniline 66 (1.0 g, 4.3 mmol) was taken up in 20 mL of THF
and added to a solution of potassium bifluoride (1.7 g, 21.6 mmol) in 5 mL H 2O. The
combined solutions were stirred at room temperature for 5 h. Upon removal of THF, the
precipitate was filtered and rinsed using ethyl acetate. Potassium (4-amino-3-methyl-5nitrophenyl) trifluoroborate (88) was produced as an orange solid (1.0 g, 93%). 1H NMR
(DMSO-d6) δ 7.81 (s, 1 H), 7.31, (s, 1 H), 6.78 (s, 2 H), 2.15 (s, 3 H).

13

C NMR (DMSO-d6)

δ 143.2, 141.4, 131.2, 125.6, 123.8, 18.3.

6-Bromo-4-methyl-2-propylbenzimidazole (95).

Butyraldehyde 41 (3.1 mL, 34.6 mmol) was added to a 250 mL flask containing 4bromo-2-methyl-6-nitroaniline 66 (4.0 g, 17.3 mmol) and sodium dithionite (18.1 g, 103.9
mmol) in 80 mL of 50% MeOH in H2O. The reaction was stirred at reflux for 5 h. The
methanol was removed via rotary evaporator. To the remaining aqueous solution, an
additional 40 mL of water was added and the mixture was extracted using EtOAc (3 x 80
mL). The organic layer was dried using magnesium sulfate. After filtration, the organic layer
was removed via rotary evaporator and the resulting solid was dried in the oven producing
6-Bromo-4-methyl-2-propylbenzimidazole 95 as a white solid (4.3 g, 97%). 1H NMR
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(DMSO-d6) δ 7.47 (s, 1H), 7.08 (s, 1H), 2.77 (t, 2H), 2.47 (s, 3H), 1.79 (m, 2H), 0.95 (t, 3H);
13

C NMR (DMSO-d6) δ 155.7,124.0, 113.1, 30.5, 20.9, 16.4, 13.6; HRMS (ESI-QTOF): m/z

Calcd for C11H13N2Br + H+: 253.0340, found: 253.0323.

Potassium (1-((2’-cyano-[1,1’-biphenyl]-4-yl)methyl)-4-methyl-2-propylbenz-imidazol 6-yl) trifluoroborate (115)

Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate 65 (1.0 g, 3.6 mmol)
was added to a solution of KOtBu (1.2 g, 10.7 mmol) in DMSO (20 mL) and stirred for 30
min at room temperature. 4’-(bromomethyl)-[1,1’-biphenyl]-2-carbonitrile 45 (1.0 g, 3.7
mmol) was then added to the reaction mixture and stirred for 2 h at room temperature. H 2O
(80 mL) was then added to the reaction mixture producing a white precipitate. The
precipitated material was filtered, rinsed with THF and then dried, producing potassium (1((2’-cyano-[1,1’-biphenyl]-4-yl)methyl)-4-methyl-2-propylbenz-imidazol -6-yl) trifluoroborate
115 as a white solid (1.5 g, 91% yield). 1H NMR (DMSO-d6) δ 7.9-7.1 (m, 10 H), 5.55 (s, 2
H), 2.83 (t, 2 H), 2.49 (s, 3 H), 1.75 (m, 2 H), 0.94 (t, 3 H).

13

C NMR (DMSO-d6) δ 155.4,

144.4, 143.9, 138.4, 137.4, 135.1, 134.3, 134.0, 130.6, 129.6, 128.7, 127.0, 119.0, 114.0,
110.6, 46.1, 29.1, 21.2, 17.0, 14.3.
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Potassium(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propyl-benzimidazole-6-yl)
trifluoroborate (117)

Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate 65 (2.0 g, 7.1 mmol)
was added to a solution of KOtBu (2.4 g, 21 mmol) in DMSO (20 mL) and stirred for 30 min
at room temperature. 4’-Bromomethyl-[1,1’-biphenyl]-methyl ester 14 (2.2 g, 7.1 mmol) was
then added to the reaction mixture and stirred for 2 h at room temperature. A solution of 2 g
KOH (35 mmol) in H2O (80 mL) was then added to the reaction mixture and stirred for an
additional 5 h at room temperature. The solution was adjusted to pH 4 using AcOH,
producing a white precipitate. The precipitated material was filtered, rinsed with THF and
then

dried,

yielding

potassium

(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propyl-

benzimidazole-6-yl) trifluoro-borate (117) as a white solid (3.2 g, 93% yield). 1H NMR
(DMSO-d6) δ 7.22-7.72 (m, 10H), 5.80 (s, 2H), 3.19 (t, 2H), 2.54 (s, 3H), 1.76 (m, 2H), 0.96
(t, 3H);

13

C NMR (DMSO-d6) δ 170.2, 152.8, 141.2, 141.0, 134.8, 132.2, 131.6, 131.2,

129.8, 129.5, 129.4, 128.1, 126.9, 122.2, 112.1, 47.4, 27.3, 21.5, 17.1, 14.1; HRMS (ESIQTOF): m/z Calcd for C25H23O2N2BF3K + H+: 491.1520, found: 491.1513.
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4’-((1,7’-Dimethyl-2’-propyl-[2,5’-dibenzimidazol]-1’-yl) methyl)-[1,1’-biphenyl]-2-carbonitrile (46).

2-Bromo-1-methylbenzimidazole (54, 50 mg, 0.24 mmol) and potassium (1-((2’cyano-[1,1’-biphenyl]-4-yl)methyl)-4-methyl-2-propylbenz-imidazol

-6-yl)

trifluoroborate

(115,123 mg, 0.26 mmol) were combined with KOH (39.9 mg, 0.71 mmol) and 5 mol%
PdCl2dppf (8.7 mg, 0.012 mmol) in a 1:1 mixture of THF and MeOH (4 mL). The mixture
was heated at 120oC, in a sealed tube, by microwave irradiation for 10 minutes. The
solution was filtered through Celite and then 12 mL of H2O was added. The resulting
precipitate was filtered and dried in oven producing 4’-((1,7’-dimethyl-2’-propyl-[2,5’dibenzimidazol]-1’-yl) methyl)-[1,1’-biphenyl]-2-carbo-nitrile (#) (106 mg, 91%). 1H NMR
(DMSO-d6) δ 7.9-7.1 (m, 14 H), 5.67 (s, 2 H), 3.80 (s, 3 H), 2.90 (t, 2 H), 2.61 (s, 3 H), 1.80
(m, 2 H), 0.97 (t, 3 H).
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Telmisartan (1).

2-bromo-1-methyl-benzimidazole (54, 40 mg, 0.19 mmol) and Potassium(1-(2’carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propyl-benzimidazole-6-yl)

trifluoroborate

(117)

(97.6 mg, 0.20 mmol) were combined with KOH (31.9 mg, 0.57 mmol) and 2 mol%
PdCl2dppf (2.8 mg, 0.004 mmol) in a 1:1 mixture of H2O and EtOH (4 mL). The solution was
heated using microwave irradiation, in a sealed tube, with stirring for 30 minutes at 150°C.
Temperature was monitored using an IR temperature sensor. The solution was filtered
through Celite. To the filtrate, 10 mL of H2O was added and the pH was adjusted to 4 using
AcOH.

The resulting precipitate was filtered and dried in oven producing telmisartan

(86.7mg, 89% yield). 1H NMR (CDCl3) δ 8.41 (d, 1H), 8.04 (d, 1H), 7.00-7.52 (m, 12H),
5.43(s, 2H), 3.76 (s, 3H), 3.16 (t, 2H), 2.73 (s, 2H), 2.02 (m, 2H), 1.18 (t, 3H);

13

C NMR

(CDCl3) δ 172.9, 158.2, 155.7, 145.2, 144.5, 143.3, 142.7, 137.2, 136.2, 135.6, 135.3,
132.1, 131.9, 131.0, 130.6, 130.4, 129.0, 128.8, 125.2, 124.9, 124.8, 123.5, 121.4, 113.0,
111.0, 50.5, 33.5, 31.7, 24.1, 18.6, 15.8; HRMS (ESI-QTOF): m/z Calcd for C33H30O2N4 +
H+: 515.2447, found: 515.2468.
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Proof of Concept Suzuki Reactions with 2-Bromo-1-methylbenzimidazole
1-Methyl-2-phenylbenzimidazole (111)

2-bromo-1-methylbenzimidazole 54 (50 mg, 0.24 mmol) and phenyl boronic acid 110
(31.8 g, 0.26 mmol) were combined in a CEM microwave test tube. To the tube
triethylamine (100 μL, 0.71 mmol), palladium acetate (2.7 mg, 12 μmol) and triphenyl
phosphine (9.3 mg, 36 μmol) were added. Finally, 4 mL of DMF was added the mixture was
heated under microwave irradiation for 10 min at 150oC. The reaction was monitored by
HPLC and produced a 98% relative conversion to 111. Product was confirmed by mass, but
was not isolated or characterized further.

2-(4-amino-3-nitrophenyl)-1-methylbenzimidazole (113)

2-bromo-1-methylbenzimidazole 54 (50 mg, 0.24 mmol) and 4-amino-3-nitrophenyl
boronic acid pinacol ester 112 (68.8 g, 0.26 mmol) were combined in a CEM microwave test
tube. To the tube triethylamine (100 μL, 0.71 mmol), palladium acetate (2.7 mg, 12 μmol)
and triphenyl phosphine (9.3 mg, 36 μmol) were added. Finally, 4 mL of DMF was added
the mixture was heated under microwave irradiation for 10 min at 150oC. The reaction was
monitored by HPLC and produced a 90% relative conversion to 113. Product was confirmed
by mass, but was not isolated or characterized further.

2-(4-amino-3-methyl-5-nitrophenyl)-1-methylbenzimidazole (40)
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2-bromo-1-methylbenzimidazole 54 (50 mg, 0.24 mmol) and 4-amino-3-methyl-5nitrophenyl boronic acid pinacol ester 83 (72.5 g, 0.26 mmol) were combined in a CEM
microwave test tube. To the tube KOH (39.9 mg, 0.71 mmol), palladium acetate (2.7 mg, 12
μmol) and triphenyl phosphine (9.3 mg, 36 μmol) were added. Finally, 4 mL of a 1:1 mixture
of ACN and MeOH was added and the mixture was heated under microwave irradiation for
20 min at 150oC. The reaction was monitored by HPLC and produced a 80% relative
conversion to 40. Product was confirmed by mass, but was not isolated or characterized
further.

1,7’-dimethyl-2’-propyl-2,6’-dibenzimidzaole (10)

2-bromo-1-methylbenzimidazole

54

(50

mg,

0.24

mmol)

and

(4-methyl-2-

propylbenzimidazol-6-yl) boronic acid pinacol ester 87 (122.8 g, 0.26 mmol) were combined
in a CEM microwave test tube. To the tube KOH (39.9 mg, 0.71 mmol), palladium acetate
(2.7 mg, 12 μmol) and triphenyl phosphine (9.3 mg, 36 μmol) were added. Finally, 4 mL of
MeOH was added and the mixture was heated under microwave irradiation for 20 min at
150oC. The reaction was monitored by HPLC and produced a 46% relative conversion to
10. Product was confirmed by mass, and matched premade standard.
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Procedure for Suzuki cross coupling reaction using Pd/G and recycling the
heterogeneous catalyst.
2-bromo-1-methyl-benzimidazole (54, 20 mg, 0.094 mmol) was dissolved in a
mixture of 2 mL H2O:EtOH (1:1) and placed in a 10 mL microwave tube. To this was added
117 (48.8 mg, 0.099 mmol), and potassium hydroxide (21.3mg, 0.38 mmol). The palladium
on graphene catalyst (Pd/G) (2.5 mg, 1.9 µmol) was then added, and the tube was sealed
and heated under microwave irradiation (250 W, 2.45 MHz) at 150 °C for 20 minutes. Upon
the completion of the reaction period, the reaction mixture was diluted with 2 mL of 10
mg/mL KOH in EtOH and centrifuged to remove the solid catalyst. The EtOH/KOH washing
were repeated twice to ensure the complete dissolution of the product from the surface of
the catalyst.

The solution was decanted and the solvent was partially concentrated in

vacuo. After adjusting the pH of the remaining solution to 4 using AcOH, the precipitated
telmisartan product was isolated by filtration and dried in the oven (76% isolated yield). In
case of recycling the Pd/G nanoparticles, the solid catalyst was removed by centrifugation
and added to the next reaction mixture using fresh reagents as indicated above. The
reaction solution was heated in the microwave at 150 °C for 20 minutes and the same
purification was applied, affording telmisartan with an isolated yield of 68% and 62% in the
second and third reactions, respectively.

Procedure for Flow Reactions.
A mixture of 3 (1 equiv., 0.2 M) and KOtBu (3 equiv.) in NMP was stirred in the first
inlet reservoir. A second inlet solution containing 4 (1 equiv., 0.2 M) in NMP was prepared,
and each were pumped at 0.25 mL/min through a T-joint into a Vapourtec E-series. The
reaction mixture was flowed through a 10 mL reactor coil at 100°C. Directly after the first
coil, a third pump introduced a third solution containing aqueous KOH (10 equiv., 1 M) at
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0.5 mL/min. The combined stream was pumped into a second 10 mL reactor coil at 120°C.
The outlet was collected in a reservoir then combined with a fourth solution containing
bromobenzimidazole 6 (1.2 equiv., 0.05 M) in a 50/50 mixture of NMP/H2O. This combined
stream was then pumped into a ThalesNano X-cube at 0.1 mL/min through two cartridges
containing 100 mg of catalyst (SiliaCat® DPP-Pd) kept at 180°C. The final outlet was
collected (2 mL, 20 min) and diluted 4x with H2O and acidified using AcOH. The resulting
precipitate was filtered and stirred in chloroform. The remaining solid was discarded and the
chloroform was removed by rotary evaporator. The residue was taken up in a dilute
aqueous KOH solution and acidified using AcOH. The precipitate was filtered and dried to
produce 1 (20.7 mg, 81% yield, 97% purity by HPLC).
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C NMR: (4-Amino-3-methyl-5-nitrophenyl) boronic acid pinacol ester (83)
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H NMR: Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65)
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C NMR: Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65)

H NMR: Potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate (88)
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C NMR: Potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate (88)
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C NMR: 6-Bromo-4-methyl-2-propylbenzimidazole (95)
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1

H NMR: 4’-((1,7’-Dimethyl-2’-propyl-[2,5’-dibenzimidazol]-1’-yl) methyl)-[1,1’-
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biphenyl]-2-carbo-nitrile (46)
1

H NMR: Potassium(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propyl-

133

benzimidazole-6-yl) trifluoroborate (117)
13

C NMR: Potassium(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propyl-
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benzimidazole-6-yl) trifluoroborate (117)
1

H NMR: Telmisartan (1)
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13

C NMR: Telmisartan (1)
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115

1

H NMR: 2-Bromo-1-methylbenzimidazole (54)

116

13

C NMR: 2-Bromo-1-methylbenzimidazole (54)

117

1

H NMR: N-(4-Bromo-2-methyl6-nitrophenyl)butyramide (77)

118

13

C NMR: N-(4-Bromo-2-methyl6-nitrophenyl)butyramide (77)

119

1

H NMR: (4-Amino-3-methyl-5-nitrophenyl) boronic acid pinacol ester (83)

120

13

C NMR: (4-Amino-3-methyl-5-nitrophenyl) boronic acid pinacol ester (83)

121

1

H NMR: (4-Methyl-2-propylbenzimidazol-6-yl) boronic acid pinacol ester (87)

122

13

C NMR: (4-Methyl-2-propylbenzimidazol-6-yl) boronic acid pinacol ester (87)

123

1

H NMR: Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65)

124

13

C NMR: Potassium (4-methyl-2-propyl-benzimidazol-6-yl) trifluoroborate (65)

125

1

H NMR: Potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate (88)

126

13

C NMR: Potassium (4-amino-3-methyl-5-nitrophenyl) trifluoroborate (88)

127

1

H NMR: 6-Bromo-4-methyl-2-propylbenzimidazole (95)

128

13

C NMR: 6-Bromo-4-methyl-2-propylbenzimidazole (95)

129

1

H NMR: Potassium (1-((2’-cyano-[1,1’-biphenyl]-4-yl)methyl)-4-methyl-2propylbenzimidazol -6-yl) trifluoroborate (115)

130

13

C NMR: Potassium (1-((2’-cyano-[1,1’-biphenyl]-4-yl)methyl)-4-methyl-2propylbenzimidazol -6-yl) trifluoroborate (115)

131

1

H NMR: 4’-((1,7’-Dimethyl-2’-propyl-[2,5’-dibenzimidazol]-1’-yl) methyl)-[1,1’biphenyl]-2-carbo-nitrile (46)

132

1

H NMR: Potassium(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propylbenzimidazole-6-yl) trifluoroborate (117)

133

13

C NMR: Potassium(1-(2’-carboxy-[1,1’-biphenyl]-4-yl)-4-methyl-2-propylbenzimidazole-6-yl) trifluoroborate (117)

134

1

H NMR: Telmisartan (1)

135

13

C NMR: Telmisartan (1)
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